Stock Code:3105

1

WIN SEMICONDUCTORS CORP. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

With Independent Auditors' Review Report For the Three Months Ended March 31, 2022 and 2021

Address: No.69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan Telephone: 886-3-397-5999

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

	Contents	Page		
1. Cove	r Page	1		
2. Table	2. Table of Contents			
3. Indep	3. Independent Auditors' Review Report			
4. Cons	olidated Balance Sheets	4		
5. Cons	olidated Statement of Comprehensive Income	5		
6. Cons	olidated Statement of Changes in Equity	6		
7. Cons	olidated Statement of Cash Flows	7		
8. Notes	s to the Consolidated Financial Statements			
(1)	Company history	8		
(2)	Approval date and procedures of the consolidated financial statements	8		
(3)	New standards, amendments and interpretations adopted	8~9		
(4)	Summary of significant accounting policies	10~11		
(5)	Significant accounting assumptions and judgments, and major sources of estimation uncertainty	12		
(6)	Explanation of significant accounts	12~52		
(7)	Related-party transactions	53~54		
(8)	Pledged assets	54		
(9)	Commitments and contingencies	55		
(10)	Losses due to major disasters	55		
(11)	Subsequent events	55		
(12)	Other	55~56		
(13)	Other disclosures			
	(a) Information on significant transactions	58~62		
	(b) Information on investments	63		
	(c) Information on investment in mainland China	64~65		
	(d) Information on major shareholders	65		
(14)	Segment information	57		



安侯建業辟合會計師事務府

台北市110615信義路5段7號68樓(台北101大樓) 68F., TAIPEI 101 TOWER, No. 7, Sec. 5, Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電話 Tel + 886 2 8101 6666 傳真 Fax + 886 2 8101 6667 網址 Web home.kpmg/tw

Independent Auditors' Review Report

To the Board of Directors of WIN Semiconductors Corp.:

Introduction

We have reviewed the accompanying consolidated balance sheets of WIN Semiconductors Corp. and subsidiaries as of March 31, 2022 and 2021, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2022 and 2021, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standards ("IASs") 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with Statement of Auditing Standards 65, "Review of Financial Information Performed by the Independent Auditor of the Entity". A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the generally accepted auditing standards and consequently, does not enable us to obtain assurance that we would become aware of any significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Unqualified Conclusion

Based on our reviews and the review report of another auditor (please refer to Other Matter Paragraph), nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of WIN Semiconductors Corp. and subsidiaries as of March 31, 2022 and 2021, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2022 and 2021 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.



Other Matter

We did not review the financial statements for the three months ended March 31, 2022, of certain investments accounted for using the equity method. That financial statements for the three months ended March 31, 2022 were reviewed by another auditor, whose review report has been furnished to us, and our conclusion, insofar as it relates to the amounts included in these investments, is based solely on the review report of another auditor. The investment accounted for using the equity method amounted to \$9,863,647 thousand, constituting 13.32% of consolidated total assets as of March 31, 2022, the related share of profit of associates and joint ventures accounted for using the equity method amounted to \$115,853 thousand, and the related share of other comprehensive income of associates and joint ventures accounted for using the equity 9.99% and 5.82% of consolidated total comprehensive income and loss for the three months ended March 31, 2022, respectively.

The engagement partners on the reviews resulting in this independent auditors' review report are Chia-Chien Tang and Ming-Hung Huang.

KPMG

Taipei, Taiwan (The Republic of China) May 13, 2022

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) Reviewed only, not audited in accordance with the generally accepted auditing standards as of March 31, 2022 and 2021

WIN Semiconductors Corp. and Subsidiaries

Consolidated Balance Sheets

March 31, 2022, December 31, and March 31, 2021

(Expressed in Thousands of New Taiwan Dollars)

		March 31, 202		December 31, 2	021	March 31, 20	21			1	March 31, 202	2	December 31, 2	021	March 31, 202	21
	Assets Current assets:	Amount	%	Amount	%	Amount	%		Liabilities and Equity		Amount	%	Amount	%	Amount	<u>%</u>
1100	Cash and cash equivalents (Note 6(a))	\$ 14,207,296	19	16,331,759	22	22,333,515	32	2100	Current liabilities:	<i>•</i>	11.504					
1110	Current financial assets at fair value through profit or	* , ,	19	10,551,759	22	22,555,515	32	2100	Short-term borrowings (Notes 6(n), 6(ad) and 8)	\$	11,594	-	-	-	-	-
1110	loss (Note 6(b))	56,557	-	61,875	-	895,581	1	2120	Current financial liabilities at fair value through profit or loss (Notes 6(b) and 6(p))		526,099	I	180,497	-	190,291	-
1170	Notes and accounts receivable, net (Notes 6(c) and							2130	Current contract liabilities (Note 6(x))		249,011	-	353,157	-	507,395	1
	6(x))	2,019,684	3	2,717,560	3	1,999,433	3	2170	Notes and accounts payable (Note 7)		1,530,971	2	2,162,825	3	1,943,421	3
1310	Inventories (Note 6(e))	6,294,761	8	6,670,737	9	5,945,195	8	2200	Other payables (Note 6(u))		8,371,384	12	4,218,686	6	8,468,027	12
1400	Current biological assets (Note 6(f))	77,850	-	138,494	-	111,468	-	2280	Current lease liabilities (Notes 6(q) and 6(ad))		123,352	-	122,882	-	89,108	-
1470	Other current assets (Notes 6(d) and 6(m))	551,510	1	534,427		462,131	1	2399	Other current liabilities		223,242		176,905	-	170,069	_
	Total current assets	23,207,658	31	26,454,852	35	31,747,323	45		Total current liabilities		11,035,653	15	7,214,952	9	11,368,311	16
	Non-current assets:								Non-current liabilities:							
1510	Non-current financial assets at fair value through profit or loss (Note 6(b))	1,941,159	3	1,822,433	2	969,440	1	2530	Bonds payable (Notes 6(p) and 6(ad))		13,329,290	18	13,286,639	18	13,159,502	19
1517	Non-current financial assets at fair value through							2540	Long-term borrowings (Notes 6(o), 6(ad) and 8)		13,519,589	19	15,992,820	22	11,535,565	17
	other comprehensive income (Note 6(b))	2,097,104	3	2,186,577	3	6,758,572	10	2570	Deferred tax liabilities		30,184	-	-	-	12,450	-
1550	Investments accounted for using equity method							2580	Non-current lease liabilities (Notes 6(q) and 6(ad))		1,030,059	1	1,034,327	1	595,501	1
	(Note 6(g))	10,582,420	14	10,405,398	14	796,952	1	2600	Other non-current liabilities (Notes 6(ad) and 7)		232,442		243,424		247,292	
1600	Property, plant and equipment (Notes 6(i), 7 and 8)	28,638,396	39	27,783,997	37	24,675,580	35		Total non-current liabilities		28,141,564	38	30,557,210	41	25,550,310	37
1755	Right-of-use assets (Notes 6(j) and 8)	1,243,457	2	1,255,616	2	769,294	1		Total liabilities		39,177,217	53	37,772,162	50	36,918,621	53
1760	Investment property (Note 6(k))	1,052,619	1	1,053,948	1	1,057,935	2		Equity (Notes 6(g), 6(h), 6(p), 6(u) and 6(v)):							
1780	Intangible assets (Note 6(1))	620,380	1	641,885	1	594,916	1	3110	Ordinary shares		4,239,764	6	4,239,764	6	4,240,414	6
1830	Non-current biological assets (Note 6(f))	383,660	-	389,952	1	339,772	-	3200	Capital surplus		9,970,823	13	9,969,914	13	9,963,079	14
1840	Deferred tax assets	510,891	1	417,116	1	258,303	-	3300	Retained earnings		17,451,067	24	19,960,265	27	13,912,031	20
1915	Prepayments for business facilities	3,312,267	4	2,153,533	3	1,785,448	3	3400	Other equity interests		1,076,972	1	768,065	1	3,527,944	5
1990	Other non-current assets (Notes 6(m) and 8)	483,132	1	328,851		395,577	1		Total equity attributable to owners of parent		32,738,626	44	34,938,008	47	31,643,468	
	Total non-current assets	50,865,485	69	48,439,306	65	38,401,789	55	36XX	Non-controlling interests		2,157,300	3	2,183,988	3	1,587,023	2
									Total equity	_	34,895,926	47	37,121,996	50	33,230,491	47
	Total assets	\$ <u>74,073,143</u>	100	74,894,158	100	70,149,112	100		Total liabilities and equity	\$	74,073,143	<u>100</u>	74,894,158	100	70,149,112	<u>100</u>

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) Reviewed only, not audited in accordance with generally accepted auditing standards

WIN Semiconductors Corp. and Subsidiaries

Consolidated Statement of Comprehensive Income

For the three months ended March 31, 2022 and 2021

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Common Share)

				months	ended March	31
			2022		2021	
		_	Amount	<u>%</u>	Amount	<u>%</u>
4000	Operating revenue (Notes 6(b), 6(g) and 6(x))	\$	5,596,993	100	6,009,383	100
5000	Operating costs (Notes 6(e), 6(f), 6(g), 6(i), 6(j), 6(q), 6(s), 6(v), 6(y), 7 and 12)	_	(3,882,832)	(69)	(3,997,649)	<u>(67</u>)
	Gross profit from operating	_	1,714,161	31	2,011,734	33
	Operating expenses (Notes 6(c), 6(i), 6(j), 6(k), 6(q), 6(s), 6(v), 6(y), 7 and 12):					
6100	Selling expenses		(85,803)	(2)	(90,063)	(1)
6200	Administrative expenses		(365,141)	(6)	(402,155)	(7)
6300	Research and development expenses		(347,006)	(6)	(324,018)	(5)
6450	Reversal of expected credit impairment	_	7		48	
	Total operating expenses	_	(797,943)	(14)	(816,188)	(13)
	Net operating income		916,218	17	1,195,546	20
	Non-operating income and expenses (Notes 6(b), 6(g), 6(i), 6(p), 6(q), 6(z) and 7):	_	<u> </u>			
7100	Interest income		5,414	-	7,601	-
7010	Other income		81,574	1	16,616	_
7020	Other gains and losses		6,602	-	274,373	5
7020	Finance costs		(80,501)	(1)	(68,582)	(1)
				· · /		
7060	Share of profit (loss) of associates and joint ventures accounted for using equity method, net	-	61,455	1	(39,064)	
-	Total non-operating income and expenses	-	74,544	1	190,944	3
7900	Profit before tax		990,762	18	1,386,490	23
7950	Tax expense (Note 6(t))	_	(204,704)	(4)	(291,334)	(5)
	Profit	_	786,058	14	1,095,156	18
8300	Other comprehensive income:					
8310	Components of other comprehensive income that will not be reclassified to profit or loss (Notes 6(g) and 6(u))					
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income		(84,825)	(1)	38,864	1
8320	Share of other comprehensive income of associates and joint ventures accounted for using equity method		579		,	
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss		-	-	-	-
	Total components of other comprehensive income (loss) that will not be reclassified to	-	(84.240)	(1)	29.964	1
02(0	profit or loss	-	(84,246)	<u>(1</u>)	38,864	<u> </u>
8360	Components of other comprehensive income that will be reclassified to profit or loss (Notes 6(g) and 6(u))					
8361	Exchange differences on translation of foreign financial statements		387,707	7	(45,624)	(1)
8370	Share of other comprehensive income of associates and joint ventures accounted for using equity method		70,523	1	(7,009)	-
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	_		_		
	Total components of other comprehensive income (loss) that will be reclassified to profit					
	or loss	_	458,230	8	(52,633)	(1)
8300	Other comprehensive income, net		373,984	7	(13,769)	
8500	Total comprehensive income	\$_	1,160,042	21	1,081,387	18
	Profit (loss) attributable to:	-				
8610	Profit attributable to owners of parent	\$	882,221	16	1,151,424	19
8620	Profit (losses) attributable to non-controlling interests		(96,163)	(2)	(56,268)	(1)
	()	\$	786,058	14	1,095,156	18
	Comprehensive income (loss) attributable to:	Ψ=	700,050		1,075,150	
8710	Comprehensive income (ioss) attributable to.	\$	1,186,730	21	1,147,403	10
		Ф				19
8720	Comprehensive income (loss), attributable to non-controlling interests	\$	(26,688) 1,160,042	- 21	(66,016) 1,081,387	(1) 18
	Earnings per common share (expressed in New Taiwan dollars) (Note 6(w))	_				
9750	Basic earnings per share	<u>\$</u>	2.08		2.72	
9850	Diluted earnings per share	\$	2.07		2.71	
		=				

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) Reviewed only, not audited in accordance with generally accepted auditing standards

WIN Semiconductors Corp. and Subsidiaries

Consolidated Statement of Changes in Equity

For the three months ended March 31, 2022 and 2021

(Expressed in Thousands of New Taiwan Dollars)

					Equ	uity attributab	le to owners of p						
								Other equi	ty interests				
					Retained earnings		Exchange	Unrealized gains (losses) on financial assets	Other				
	(Ordinary shares	Capital surplus	Legal reserve	Unappropriated retained earnings	Total retained earnings	differences on translation of foreign financial statements	measured at fair value through other comprehensive income	unearned compensation for restricted shares of employees	Total other equity interests	Total equity attributable to owners of parent	Non-controlling interests	Total equity
	\$	4,240,564	9,323,098	2,515,700	14,485,321	17,001,021	(202,205)	3,780,846	(65,738)	3,512,903	34,077,586	1,652,866	35,730,452
					(4,240,414)	(4,240,414)					(4,240,414)	(4,240,414)
2021		-	-	-	1,151,424	1,151,424	-	-	-	-	1,151,424	(56,268)	
nded March 31, 2021	_	-	-		-	-	(42,885)	38,864	-	(4,021)			/
ded March 31, 2021	_	-	-		1,151,424	1,151,424	(42,885)	38,864	-	(4,021)	1,147,403	(66,016)	
employees		-	-	-	-	-	-	-	19,062	19,062	19,062	-	19,062
for employees		(150)	150	-	-	-	-	-	-	-	-	-	-
ds issued		-	639,583	-	-	-	-	-	-	-	639,583	-	639,583
			248								248	173	421
	\$	4,240,414	9,963,079	2,515,700	11,396,331	13,912,031	(245,090)	3,819,710	(46,676)	3,527,944	31,643,468	1,587,023	33,230,491
	\$ <u> </u>	4,239,764	9,969,914	3,172,722	16,787,543	19,960,265	(269,409)	1,044,071	(6,597)	768,065	34,938,008	2,183,988	37,121,996
		_	_	-	(3,391,811)	(3,391,811)	_	-	-	-	(3,391,811) -	(3,391,811)
2022		-	-	-	882,221	882,221	-	-	-	-	882,221	(96,163)	/
nded March 31, 2022		-	-	-	-	-	388,755	(84,246)	-	304,509	304,509	69,475	373,984
ded March 31, 2022	_	-	-	-	882,221	882,221	388,755	(84,246)		304,509	1,186,730	(26,688)	1,160,042
employees	_	-	-	-	-	-	-	-	4,398	4,398	4,398	-	4,398
equity method		-	909	-	392	392	-	-	-	-	1,301	-	1,301
	\$	4,239,764	9,970,823	3,172,722	14,278,345	17,451,067	119,346	959,825	(2,199)	1,076,972	32,738,626	2,157,300	34,895,926
	<u> </u>	4,239,764	9,970,823	3,1/2,/22	14,2/8,345	17,451,067	119,346	959,825	(2,199)	1,0/6,9/2	32,/38,626	2,157,300	34,8

Balance at January 1, 2021

Appropriation and distribution of retained earnings: Cash dividends of ordinary shares Profit (losses) for the three months ended March 31, 2021 Other comprehensive income for the three months ended March 31, 2021 Total comprehensive income for the three months ended March 31, 2021 Compensation cost arising from restricted shares of employees Purchase and retirement of restricted shares of stock for employees Recognition of equity component of convertible bonds issued Stock option compensation cost of subsidiary Balance at March 31, 2021

Balance at January 1, 2022

Appropriation and distribution of retained earnings: Cash dividends of ordinary shares

Profit (losses) for the three months ended March 31, 2022 Other comprehensive income for the three months ended March 31, 2022 Total comprehensive income for the three months ended March 31, 2022 Compensation cost arising from restricted shares of employees Changes in equity of associates accounted for using equity method **Balance at March 31, 2022**

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) <u>Reviewed only, not audited in accordance with generally accepted auditing standards</u>

WIN Semiconductors Corp. and Subsidiaries

Consolidated Statement of Cash Flows

For the three months ended March 31, 2022 and 2021

(Expressed in Thousands of New Taiwan Dollars)

	For the three months	ended March 31
	2022	2021
Cash flows from (used in) operating activities: Profit before tax	\$ 990,762	1,386,490
Adjustments:	\$990,762	1,380,490
Adjustments to reconcile profit (loss):		
Depreciation expense	1,057,776	999,543
Amortization expense	36,328	31,407
Reversal of expected credit impairment	(7)	(48)
Net losses (gains) on financial assets or liabilities at fair value through profit or loss	274,087	(78,497)
Interest expense Interest income	80,501	68,582
Dividend income	(5,414) (81,056)	(7,601) (15,478)
Share-based payments	4,398	19,483
Share of (profit) loss of associates and joint ventures accounted for using equity method	(81,878)	39,346
Losses on disposal of property, plant and equipment	142	5,428
Property, plan and equipment and prepayments for business facilities transferred to expenses	35	917
Changes in biological assets at fair value	41,166	(9,000)
Unrealized foreign exchange (gains) losses	(16,273)	52,535
Losses on lease modification	21,721	-
Total adjustments to reconcile profit (loss) Changes in operating assets and liabilities:	1,331,526	1,106,617
Changes in operating assets:		
Decrease (increase) in financial assets at fair value through profit or loss	1,000	(129,985)
Decrease in notes and accounts receivable	697,883	38,118
Decrease (increase) in inventories	252,473	(489,890)
Decrease in biological assets	21,677	113,888
(Increase) decrease in other current assets	(16,707)	87,822
Total changes in operating assets	956,326	(380,047)
Changes in operating liabilities:	(104.140)	(27.021)
Decrease in contract liabilities (Decrease) increase in notes and accounts payable	(104,146) (631,854)	(27,031) 148,753
Decrease in other payables	(668,067)	(271,853)
Increase in other current liabilities	46,337	12,866
Increase in other non-current liabilities	39	387
Total changes in operating liabilities	(1,357,691)	(136,878)
Total changes in operating assets and liabilities	(401,365)	(516,925)
Cash inflow generated from operations	1,920,923	1,976,182
Dividends received	8,745	7,660
Income taxes paid	(1,813)	(1,400) 1,982,442
Net cash flows from operating activities Cash flows from (used in) investing activities:	1,927,833	1,962,442
Proceeds from capital reduction of financial assets at fair value through other comprehensive income	5,667	-
Acquisition of financial assets at fair value through profit or loss	(45,162)	(36,966)
Proceeds from disposal of financial assets at fair value through income	9,969	-
Proceeds from capital reduction of financial assets at fair value through profit or loss	5,389	901
Acquisition of property, plant and equipment	(975,495)	(1,359,554)
Proceeds from disposal of property, plant and equipment	-	243
Acquisition of intangible assets	(18,507)	(29,692)
Increase in other non-current assets Increase in prepayments for business facilities	(162,732) (344,307)	(53,926) (474,205)
Interest received	6,038	7,172
Dividends received	72,311	7,818
Net cash flows used in investing activities	(1,446,829)	(1,938,209)
Cash flows from (used in) financing activities:		
Issuance of convertible bonds payable	-	13,902,774
Increase in short-term loans	11,594	-
Proceeds from long-term debt	1,453,200	1,653,750
Repayments of long-term debt	(4,123,113)	(1,558,000)
Repayments of lease liabilities (Decrease) increase in other non-current liabilities	(27,389) (11,021)	(29,665) 11,290
Interest paid	(32,568)	(20,683)
Net cash flows (used in) from financing activities	(2,729,297)	13,959,466
Effect of exchange rate changes on cash and cash equivalents	123,808	(26,454)
Net (decrease) increase in cash and cash equivalents	(2,124,463)	13,977,245
Cash and cash equivalents at beginning of period	16,331,759	8,356,270
Cash and cash equivalents at end of period	\$ <u>14,207,296</u>	22,333,515

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) Reviewed only, not audited in accordance with generally accepted auditing standards

WIN Semiconductors Corp. and Subsidiaries Notes to the Consolidated Financial Statements March 31, 2022 and 2021

(Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(1) Company history:

WIN Semiconductors Corp. (the "Company") was incorporated on October 16, 1999 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The address of the Company's registered office is No. 69, Keji 7th Rd., Hwaya Technology Park, Guishan Dist., Taoyuan City, Taiwan.

The main operations of the Company and its subsidiaries (together referred to as "the Group") are as follows:

- (a) Researching, developing, manufacturing, and selling of GaAs wafers.
- (b) Developing hog farming technology and trading.
- (c) Researching, manufacturing and selling of high-density gene chips, biochip optical readers, microelectrophoresis analyzers and diagnostic tool for endometrial cancer.

(2) Approval date and procedures of the consolidated financial statements:

These consolidated financial statements were reported for issuance by the Board of Directors as of May 13, 2022.

(3) New standards, amendments and interpretations adopted:

(a) The impact of the International Financial Reporting Standards ("IFRSs") endorsed by the Financial Supervisory Commission, R.O.C. ("FSC") which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2022:

- Amendments to IAS 16 "Property, Plant and Equipment-Proceeds before Intended Use"
- Amendments to IAS 37 "Onerous Contracts Cost of Fulfilling a Contract"
- Annual Improvements to IFRS Standards 2018–2020
- Amendments to IFRS 3 "Reference to the Conceptual Framework"

(b) The impact of IFRS issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Effective date per IASB		
Amendments to IAS 1 "Classification of Liabilities as Current or Non-current"	The amendments aim to promote consistency in applying the requirements by helping companies determine whether, in the statement of balance sheet, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current.	January 1, 2023	
	The amendments include clarifying the classification requirements for debt a company might settle by converting it into equity.		
Amendments to IAS 12 "Deferred Tax related to Assets and Liabilities arising from a Single Transaction"	The amendments narrowed the scope of the recognition exemption so that it no longer applies to transactions that, on initial recognition, give rise to equal taxable and deductible temporary differences.	January 1, 2023	

The Group is evaluating the impact of its initial adoption of the abovementioned standards or interpretations on its financial position and consolidated financial performance. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture"
- IFRS 17 " Insurance Contracts" and amendments to IFRS 17 " Insurance Contracts"
- Amendments to IAS 1 "Disclosure of Accounting Policies"
- Amendments to IAS 8 "Definition of Accounting Estimates"

(4) Summary of significant accounting policies:

Except the following accounting policies mentioned below, the significant accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2021. For the related information, please refer to Note 4 of the consolidated financial statements for the year ended December 31, 2021.

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 "Interim Financial Reporting" which are endorsed by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed by the FSC (hereinafter referred to IFRS endorsed by the FSC) for a complete set of the annual consolidated financial statements.

(b) Basis of consolidation

(i) List of subsidiaries in the consolidated financial statements:

			Shareholding			
			March 31,	December 31,	March 31,	
Name of investor	Name of subsidiary	Principal activity	2022	2021	2021	Remark
The Company	WIN SEMI. USA, INC.	Marketing	100.00 %	100.00 %	100.00 %	
The Company	Win Semiconductors Cayman Islands Co., Ltd. (abbrev. Win Cayman)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Venture Capital Corp. (abbrev. WVC)	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	Phalanx Biotech Group, Inc. (abbrev. PBL)	Researching, manufacturing and selling of high-density gene chips and testing service	73.67 %	73.67 %	54.48 %	(Note 1)
The Company	WIN Earn Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
The Company	WIN Chance Investment Corp.	Investment activities	100.00 %	100.00 %	100.00 %	
WVC	Phalanx Biotech Group, Inc.	Researching, manufacturing and selling of high-density gene chips and testing service	1.54 %	1.54 %	4.39 %	(Note 1)
Win Cayman	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. (abbrev. Chainwin Cayman)	Investment activities	81.23 %	81.23 %	81.69 %	(Note 1)
Chainwin Cayman	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Chance Agriculture Development Co., Ltd. (abbrev. Jiangsu Win Chance)	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	Farm feed development and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Merit Runfu Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Yield Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	i-Chainwin Technology (Cayman Islands) Co., Ltd.	Investment activities	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Win Lux Biotech (Cayman Islands) Co., Ltd.	Investment activities	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Shine Agriculture Development Co., Ltd.	Logistics management service	100.00 %	100.00 %	100.00 %	

			March 31,	December 31,	March 31,	
Name of investor	Name of subsidiary	Principal activity	2022	2021	2021	Remark
Chainwin Cayman	i-Chainwin Technology Co., Ltd.	Information software services	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Win Lux Biotech Co., Ltd.	Biotechnology service and pharmaceutical testing	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Boutique Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Sunlight Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Honor Management Technology Co., Ltd.	Logistics management service	100.00 %	100.00 %	100.00 %	
Chainwin Cayman	Jiangsu Win Fortune Agriculture Development Co., Ltd.	Developing hog farming technology and trading	100.00 %	100.00 %	-	
Chainwin Cayman	Chainwin (Huaian) AloT Co., Ltd.	Information software services	100.00 %	100.00 %	-	
Chainwin Cayman	Jiangsu Win Advane Bio-Assay Co., Ltd.	Biotechnology testing service	100.00 %	100.00 %	-	
Chainwin Cayman	Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and bioassay	100.00 %	100.00 %	-	
Jiangsu Win Chance	Jiangsu Win Wonder Agriculture Development Co., Ltd.	Developing farming technology and trading	100.00 %	100.00 %	100.00 %	
PBL	PhalanxBio, Inc.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	
PBL	Phalanx Biotech Limited. (abbrev. PBL (HK))	Investment activities	100.00 %	100.00 %	100.00 %	
PBL	Guzip Biomarkers Corporation	Developing and selling of diagnostic tool for endometrial cancer	100.00 %	100.00 %	-	
PBL (HK)	Onearray Biotech (Kunshan) Co., Ltd.	Selling of high-density gene chips and testing service	100.00 %	100.00 %	100.00 %	

Note 1: For the related information of the shareholding percentage change, please refer to Note 6(i) of the consolidated financial statements for the year ended December 31, 2021.

Note 2: The aforementioned subsidiaries were recognized based on the reviewed financial statements by the certified public accountant.

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

(c) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-time events.

(d) Income taxes

The income tax expenses have been evaluated and disclosed in accordance with paragraph B12 of IAS 34 "Interim Financial Reporting."

Income tax expenses for the period are best estimated by multiplying pre-tax income for the interim reporting period by the effective annual tax rate as forecasted by the management. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IFRSs (in accordance with IAS 34 "Interim Financial Reporting" and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Except for the following, the preparation of the consolidated financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2021. For the related information, please refer to Note 5 of the consolidated financial statements for the year ended December 31, 2021.

Information about judgments made in applying accounting policies that have the most significant effects on the amounts recognized in the consolidated financial statements is as follows:

(a) Judgment of whether the Group has substantive control over its investee

The Group holds 49% of the outstanding voting shares of Rainbow Star Group Limited and is the single largest shareholder of the investee. The remaining 51% of Rainbow Star Group Limited's shares are concentrated within specific shareholders, and therefore the Group cannot obtain more than half of the total number of Rainbow Star Group Limited directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over Rainbow Star Group Limited.

The Group holds 20.80% of the outstanding voting shares of ITEQ Corporation (hereinafter referred to as "ITEQ") and is the single largest shareholder of the investee. Although the remaining 79.20% of ITEQ's shares are not concentrated within specific shareholders, the Group still cannot obtain more than half of the total number of ITEQ directors, and it also cannot obtain more than half of the voting rights at a shareholders' meeting. As a result, it is determined that the Group has significant influence but not control over ITEQ.

(b) Judgment of whether the Group has significant influence on its investee

The Group's 32.88% shares in NFC Fund II L.P. is deemed as a mutual fund. The Group does not act as the director and is not designed as the representative of those charged with the governance of NFC Fund II L.P. As a result, it is determined that the Group does not have significant influence on NFC Fund II L.P.

(6) Explanation of significant accounts:

Except for the following disclosure, the significant account disclosure in the consolidated financial statements for the three months ended March 31, 2022, which compare with the consolidated financial statements for the year ended December 31, 2021, was not changed significantly. For the related information, please refer to Note 6 of the consolidated financial statements for the year ended December 31, 2021.

(a) Cash and cash equivalents

	Ν	March 31, 2022	December 31, 2021	March 31, 2021
Cash on hand	\$	279	321	337
Cash in bank		12,906,817	13,647,220	15,834,334
Time deposits		1,300,200	2,684,218	6,498,844
	\$	14,207,296	16,331,759	22,333,515

Refer to Note 6(aa) for currency risk of the financial assets and liabilities and the fair value sensitivity analysis of the Group.

- (b) Financial instruments
 - (i) Financial assets and liabilities at fair value through profit or loss:

		March 31, 2022	December 31, 2021	March 31, 2021
Mandatorily measured at financial assets at fair value through profit or loss:				
Non-derivative financial assets				
Stock listed on domestic markets	\$	14,197	18,541	19,292
Non-public stocks (Note)		398,433	380,417	-
Money market funds		42,360	43,334	876,289
Private fund (Note)		1,542,726	1,442,016	969,440
Total	<u></u>	1,997,716	1,884,308	1,865,021
Current	\$	56,557	61,875	895,581
Non-current		1,941,159	1,822,433	969,440
	\$	1,997,716	1,884,308	1,865,021

Note: As of March 31, 2022, December 31 and March 31, 2021, part of the private fund and non-public stocks were during the lock-up period.

	N	1arch 31, 2022	December 31, 2021	March 31, 2021
Mandatorily measured at current financial liabilities at fair value through profit or loss				
Convertible bonds with embedded derivatives	\$ <u></u>	526,099	180,497	190,291

(Continued)

The derivative financial instruments arose from the issuance of overseas convertible bonds of the Group disclosed in Note 6(p).

(ii) Non-current financial assets at fair value through other comprehensive income (FVOCI):

	March 31,		December 31,	March 31,
		2022	2021	2021
Stocks listed on domestic markets	\$	93,633	124,844	4,754,991
Stocks listed on US markets		1,352,080	1,381,391	992,464
Non-public stocks		651,391	680,342	1,011,117
	\$_	2,097,104	2,186,577	6,758,572

The Group decided to hold these equity instruments, which are not held for trading, at fair value through other comprehensive income.

For the three months ended March 31, 2022 and 2021, there were no disposals of equity investments at fair value through other comprehensive income, and the gains and losses accumulated in other equity were not transferred to retained earnings during the period.

For the three months ended March 31, 2022 and 2021, the Group received dividend income \$10,597 thousand and \$14,926 thousand, respectively, of the equity investment designated at fair value through other comprehensive income.

(iii) Sensitivity analysis in the equity price risk:

If the equity price changes, the impact to comprehensive income, using the sensitivity analysis based on the same variables except for the price index for both periods, will be as follows:

	For the three months ended March 31, 2022		For the three mo March 31,	
Prices of securities at the reporting date	After-tax other comprehensive income	After-tax profit (loss)	After-tax other comprehensive income	After-tax profit (loss)
Increasing 3%	\$62,913	12,379	202,757	579
Decreasing 3%	\$(62,913)	(12,379)	(202,757)	(579)

(iv) As of March 31, 2022, December 31 and March 31, 2021, the financial assets were not pledged. For information on the Group's credit risk and fair value information was disclosed in Note 6(aa).

(c) Notes and accounts receivable, net

]	March 31, 2022	December 31, 2021	March 31, 2021	
Notes receivable	\$	965	1,053	606	
Accounts receivable		2,019,517	2,717,312	1,998,926	
Less: loss allowance		(798)	(805)	(99)	
	\$	2,019,684	2,717,560	1,999,433	

The Group applies the simplified approach to provide for its loss allowance used for expected credit losses, which permit the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivable have been grouped based on shared credit risk characteristics and days past due, as well as incorporate forward looking information.

The loss allowance provision was determined as follows:

(i) The segment of foundry and agriculture technology:

	March 31, 2022Weighted- averageLifeGross carryingexpected lossamountrateloss all			
Not past due	\$ 1,931,188	0%	-	
Past due 1~60 days	83,182	0%	-	
Past due 61~120 days	91	0%	-	
Past due 121~180 days	-	0%~1.67%	-	
Past due more than 181 days	 -	100%		
	\$ 2,014,461			
	 D	ecember 31, 2021	l	
	oss carrying amount	Weighted- average expected loss rate	Lifetime expected credit loss allowance	

		amount	Tate	1055 and wantee
Not past due	\$	2,556,855	0%	-
Past due 1~60 days		154,719	0%	-
Past due 61~120 days		-	0%	-
Past due 121~180 days		-	0%~1.67%	-
Past due more than 181 days		-	100%	
	<u>\$</u>	2,711,574		

- -

	Gro	Lifetime expected credit loss allowance		
Not past due	\$	1,942,044	0%	-
Past due 1~60 days		46,182	0%	-
Past due 61~120 days		7,880	0%	-
Past due 121~180 days		-	1.67%~5.43%	-
Past due more than 181 days		-	100%	
	\$	1,996,106		

(ii) The segment of gene chip testing service:

	March 31, 2022			
		s carrying nount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	3,875	0%~5.13%	3
Past due 1~60 days		1,195	0%~30.12%	24
Past due 61~120 days		135	0%~41.48%	4
Past due 121~180 days		66	0%~55.56%	17
Past due more than 181 days		750	100%	750
	\$	6,021		798

	December 31, 2021			
		s carrying nount	Weighted- average expected loss rate	Lifetime expected credit loss allowance
Not past due	\$	4,927	0%~29.86%	23
Past due 1~60 days		1,060	0%~36.91%	10
Past due 61~120 days		27	0%~49.81%	-
Past due 121~180 days		11	0%~61.11%	6
Past due more than 181 days		766	100%	766
	\$	6,791		805

	March 31, 2021Weighted- averageLifetinGross carrying amountexpected loss expectedareloss allow				
Not past due	\$	2,598	0.52%~9.40%	32	
Past due 1~60 days		766	4.26%~48.02%	34	
Past due 61~120 days		14	8.58%~60.93%	1	
Past due 121~180 days		48	37.83%~77.78%	32	
Past due more than 181 days		-	100%		
	\$	3,426		99	

The movements of loss allowance were as follows:

	For the three months ended March 31, 2022		For the three months ended March 31, 2021	
Beginning balance	\$	805	148	
Impairment loss reversed		(7)	(48)	
Effect of changes in foreign exchange rates		-	<u>(1</u>)	
Ending balance	\$	798	99	

As of March 31, 2022, December 31 and March 31, 2021, the notes and accounts receivable were not discounted nor pledged.

(d) Other receivables (recognized as other current assets)

		March 31, 2022	December 31, 2021	March 31, 2021	
Other receivables	\$	35,090	23,700	22,447	
Less: loss allowance		-			
	\$ <u></u>	35,090	23,700	22,447	

As of March 31, 2022, December 31 and March 31, 2021, other receivables were not past due nor impaired.

For information on the Group's credit risk was disclosed in Note 6(aa).

(e) Inventories

	March 31, 2022		December 31, 2021	March 31, 2021
Raw materials, supplies and spare parts	\$	4,328,782	4,352,874	3,763,683
Work in process		873,970	1,291,563	1,309,623
Finished goods		1,092,009	1,026,300	871,889
	<u></u>	6,294,761	6,670,737	5,945,195

Except for cost of goods sold and inventories recognized as expenses, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	mon	ths ended	For the three months ended
	Mare	<u>ch 31, 2022</u>	March 31, 2021
Losses on valuation of inventories and obsolescence	\$	72,454	34,418
Unallocated overheads	\$	88,205	
Revenue from sale of scraps	\$	(13,903	(8,973)
Gains on physical inventory count	<u>\$</u>	(4,293)

As of March 31, 2022, December 31 and March 31, 2021, the inventories were not pledged.

(f) Biological assets

(i) List of biological assets:

	March 31, 2022		December 31, 2021	March 31, 2021
Consumable biological assets	<u>\$</u>	77,850	138,494	111,468
Bearer biological assets	\$	383,660	389,952	339,772

(ii) Movements in biological assets:

	mor	• the three nths ended ch 31, 2022	For the three months ended March 31, 2021
Beginning balance	\$	528,446	565,216
Increase due to purchase		25,441	78,951
Input costs		195,583	126,073
Depreciation expenses		(22,029)	(6,383)
Decrease due to sales and disposals		(242,701)	(318,912)
Changes in fair value less costs to sell due to price changes		(41,166)	9,000
Effect of changes in foreign exchange rates		17,936	(2,705)
Ending balance	<u>\$</u>	461,510	451,240
Current	\$	77,850	111,468
Non-current		383,660	339,772
	\$	461,510	451,240

For the three months ended March 31, 2022 and 2021, the losses and gains of \$(41,166) thousand and \$9,000 thousand, respectively, were recognized as operating costs of the consolidated statement of comprehensive income as a result of the remeasurement of biological assets at the higher of its carrying amount or fair value less costs to sell.

(iii) The numbers of the Group's biological assets were as follows:

Unit: head

	March 31,	December 31,	March 31,
	2022	2021	2021
Farrows, hogs and breeders	46,725	46,684	26,072

(iv) Fair value

There were no significant addition regarding the fair value of the Group's biological assets. For the related information, please refer to Note 6(f) of the consolidated financial statements for the year ended December 31, 2021.

(v) As of March 31, 2022, December 31 and March 31, 2021, the biological assets were not pledged.

(g) Investments accounted for using equity method

The components of investments accounted for using the equity method at the reporting date were as follows:

	March 31,	December 31,	March 31,
	2022	2021	2021
Associates	\$ <u>10,582,420</u>	10,405,398	796,952

(i) Associates

Associates which are material to the Group consisted of the followings:

		Main Operating Location/ Registered		rtion of Shareho nd Voting Right	0
Name of Associates	Main Businesses and Products	Country of the Company	March 31, 2022	December 31, 2021	March 31, 2021
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev. Jiangsu CM/Chainwin)	farming technology and	China	49 %	49 %	49 %
ITEQ Corporation (abbrev. ITEQ) (Note)	Manufactures and sells mass lamination boards, copper-clad laminates, prepreg, and electronic components	Taiwan	20.80 %	20.80 %	-

Note: In July 2021, the Group has significant influence over ITEQ, and therefore the ITEQ has become the Group's associates since July, 2021. For the related information, please refer to Note 6(g) of the consolidated financial statements for the year ended December 31, 2021.

The fair value of significant associate listed on the Taiwan Stock Exchange Corporation (TWSE) which is material to the Group is as follows:

	Ν	Aarch 31,	December 31,	
		2022	2021	
ITEQ	\$	9,557,067	11,309,197	

The following consolidated financial information of significant associates has been adjusted according to individually prepared IFRS financial statements of these associates.

The financial information of Jiangsu CM/Chainwin:

		March 31, 2022]	December 31, 2021	March 31, 2021
Current assets	\$	208,801	-	231,717	424,719
Non-current assets		1,324,450		1,304,478	1,220,696
Current liabilities		(141,887))	(127,658)	(99,224)
Non-current liabilities	_	(33,150)) _	(31,592)	(30,502)
Net assets	\$	1,358,214	=	1,376,945	1,515,689
			r M		For the three months ended March 31, 2021
Operating revenue			\$ <u> </u>		321,022
Losses			\$	(68,760)	(79,722)
Other comprehensive income			-		
Total comprehensive income			\$	(68,760)	(79,722)
			n	For the three nonths ended Iarch 31, 2022	For the three months ended March 31, 2021
Carrying amount of equity of Jiangsu CM attributable to the Group at the beginni		inwin	\$	673,302	785,949
Losses attributable to the Group				(33,693)	(39,064)
Exchange differences on translation of for statements attributable to the Group	reign	financial	_	3,543	(7,009)
Shares of net assets of Jiangsu CM/Chain	win a	at the end		643,152	739,876
Add: Effect of changes in foreign exchange	ge rat	tes	_	20,923	1,367
Carrying amount of equity of Jiangsu CM	/Cha	inwin			
attributable to the Group at the end			\$	664,075	741,243
The financial information of ITEQ:					
				March 31, 2022	December 31, 2021
Current assets			\$	24,797,178	24,375,370
Non-current assets				10,816,735	11,861,917
Current liabilities				(14,158,527)	(14,264,806)
Non-current liabilities			-	(671,531)	(657,743)
Net assets			\$	20,783,855	21,314,738

Operating revenue	For the three months ended March 31, 2022 \$ 8,269,058
Profit	\$ 809,113
Other comprehensive income	570,653
Total comprehensive income	\$ <u>1,379,766</u>
Carrying amount of equity of ITEQ attributable to the Group at the	For the three months ended <u>March 31, 2022</u>
beginning	\$ 9,678,934
Profit attributable to the Group	115,853
Comprehensive income attributable to the Group	67,559
Changes in retained earnings of associates	392
Changes in capital surplus of associates	909
Carrying amount of equity of ITEQ attributable to the Group at the end	9,863,647
Less: Goodwill	(5,245,224)
Shares of net assets of ITEQ at the end	\$4,618,423

Summary of financial information for the individually insignificant investments in associates accounted for using equity method were as follows. The aforementioned financial information was included in the consolidated financial statements of the Group:

		March 31, 2022		ber 31, 021	March 31, 2021
Total equity of the individually insignificant investments in associates	\$_	54,698		53,162	55,709
			mont	the three hs ended h 31, 2022	For the three months ended March 31, 2021
Attributable to the Group:					
Losses			\$	(282)	(282)
Other comprehensive income				-	
Total comprehensive income			\$	(282)	(282)

(ii) Pledge to secure

As of March 31, 2022, December 31 and March 31, 2021, the investments accounted for using equity method were not pledged.

(h) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

		Percentage of non-controlling interests			
		March 31,	December 31,	March 31,	
Subsidiaries	Registration	2022	2021	2021	
Chainwin Cayman	Cayman Islands	18.77 %	18.77 %	18.31 %	

The following information of the aforementioned subsidiaries have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers. Included in the information are the fair value adjustment made during the acquisition and relevant difference in accounting principles between the Group as at the acquisition date. Intragroup transactions were not eliminated in this information.

		March 31, 2022	December 31, 2021	March 31, 2021
Current assets	\$	3,756,024	4,842,182	3,744,944
Non-current assets		13,384,979	12,334,743	9,611,890
Current liabilities		(416,462)	(467,228)	(173,788)
Non-current liabilities	_	(6,082,837)	(5,974,406)	(5,061,966)
Net assets	<u></u>	10,641,704	10,735,291	8,121,080
Non-controlling interests	\$	1,997,833	2,015,403	1,495,258
			For the three months ended March 31, 2022	For the three months ended March 31, 2021
Operating revenue		5	§ <u>47,589</u>	227,774
Losses		5	\$ (463,512)	(236,152)
Other comprehensive income (loss)			369,925	(53,146)

Total comprehensive income (loss)

Losses attributable to non-controlling interests

(289, 298)

(43, 239)

(93,587)

(87,018)

\$

\$

	mo	or the three onths ended rch 31, 2022	For the three months ended March 31, 2021
Net cash flows used in operating activities	\$	(312,915)	(135,676)
Net cash flows used in investing activities		(849,534)	(1,129,988)
Net cash flows (used in) from financing activities		(47,541)	965,326
Effect of changes in foreign exchange rate		(18,866)	21,446
Decrease in cash and cash equivalents	\$	(1,228,856)	(278,892)

(i) Property, plant and equipment

The movements in property, plant and equipment were as follows:

		Land	Buildings and structures	Machinery and equipment	Factory and equipment	Other equipment	Construction in progress and inspection- awaited devices	Total
Cost:								
Balance as of January 1, 2022	\$	2,546,534	5,409,451	20,272,516	6,406,045	565,461	9,402,246	44,602,253
Additions		-	-	74,525	89,646	33,510	1,218,511	1,416,192
Reclassification (Note 1)		-	-	35,649	5,778	5,475	(10,407)	36,495
Disposals		-	(703)	(269,929)	(75,550)	(8,143)	-	(354,325)
Effect of changes in foreign exchange rates	-	-	99,559	381	1,953	2,933	303,404	408,230
Balance as of March 31, 2022	\$	2,546,534	5,508,307	20,113,142	6,427,872	599,236	10,913,754	46,108,845
Balance as of January 1, 2021	\$	2,546,534	2,445,758	22,097,218	6,180,047	642,560	6,706,796	40,618,913
Additions		-	15,896	89,366	107,298	26,759	1,329,909	1,569,228
Reclassification (Note 2)		-	468,209	188,794	230,648	(14,724)	(90,421)	782,506
Disposals		-	(38,134)	(455,764)	(54,341)	(78,454)	-	(626,693)
Effect of changes in foreign exchange rates		-	(510)	(60)	(360)	(415)	(55,609)	(56,954)
Balance as of March 31, 2021	<u></u>	2,546,534	2,891,219	21,919,554	6,463,292	575,726	7,890,675	42,287,000
Accumulated depreciation:	_							
Balance as of January 1, 2022	\$	-	1,045,218	12,327,474	3,213,613	231,951	-	16,818,256
Depreciation		-	65,934	750,981	144,642	40,870	-	1,002,427
Disposals		-	(677)	(269,813)	(75,550)	(8,143)	-	(354,183)
Effect of changes in foreign exchange rates	s _	-	1,669	200	892	1,188		3,949
Balance as of March 31, 2022	\$	-	1,112,144	12,808,842	3,283,597	265,866		17,470,449
Balance as of January 1, 2021	\$	-	921,015	12,894,424	3,019,553	361,704		17,196,696
Depreciation		-	35,607	753,004	130,525	46,941	-	966,077
Reclassification (Note 3)		-	73,108	(1)	-	(2,897)	-	70,210
Disposals		-	(38,134)	(455,764)	(48,670)	(78,454)	-	(621,022)
Effect of changes in foreign exchange rates		-	(141)	(38)	(175)	(187)		(541)
Balance as of March 31, 2021	\$	-	991,455	13,191,625	3,101,233	327,107		17,611,420
Carrying amount:	_							
Balance as of January 1, 2022	<u>\$</u>	2,546,534	4,364,233	7,945,042	3,192,432	333,510	9,402,246	27,783,997
Balance as of March 31, 2022	\$	2,546,534	4,396,163	7,304,300	3,144,275	333,370	10,913,754	28,638,396
Balance as of January 1, 2021	\$	2,546,534	1,524,743	9,202,794	3,160,494	280,856	6,706,796	23,422,217
Balance as of March 31, 2021	\$	2,546,534	1,899,764	8,727,929	3,362,059	248,619	7,890,675	24,675,580

(Continued)

- Note 1: Prepayments for business facilities and capitalized right-of-use depreciation expenses were reclassified as property, plant and equipment.
- Note 2: Prepayments for business facilities, investment property and capitalized right-of-use depreciation expenses were reclassified as property, plant and equipment.

Note 3: Investment property was reclassified as property, plant and equipment.

(i) Pledge to secure

As of March 31, 2022, December 31 and March 31, 2021, the property, plant and equipment were subject to a registered debenture to secured bank loans and line of credit, the collateral for these long-term borrowings was disclosed in Note 8.

(ii) Property, plant and equipment under construction

The Group rented some pieces of land and entered into different agreements for the construction of its new factories on the said lands. For the three months ended March 31, 2022, the Group has constructed factories amounting to \$708,150 thousand, and has recognized as construction in progress. As of March 31, 2022, the total amount of the construction is \$9,355,133 thousand, and is recognized as construction in progress.

- (iii) For the three months ended March 31, 2022 and 2021, capitalized interest expenses amounted to \$14,966 thousand and \$9,617 thousand, respectively. The annual interest rates at which these interest expenses were capitalized ranged from 0.57%~0.84% and 0.57%~0.72%, respectively.
- (j) Right-of-use assets

The movements in right-of-use assets were as follows:

		Land	Buildings and structures	Other equipment	Total
Cost:				<u>-quipinene</u>	
Balance as of January 1, 2022	\$	986,869	482,647	20,853	1,490,369
Additions		51,003	82,924	1	133,928
Disposals		(137,947)	(26,980)	(762)	(165,689)
Effect of change in foreign exchange rates		16,407	3,363	130	19,900
Balance as of March 31, 2022	<u></u>	916,332	541,954	20,222	1,478,508
Balance as of January 1, 2021	\$	530,419	393,559	13,630	937,608
Additions		-	13,373	137	13,510
Disposals		(382)	(1,667)	(910)	(2,959)
Effect of change in foreign exchange rates		(3,875)	(320)	1	(4,194)
Balance as of March 31, 2021	\$	526,162	404,945	12,858	943,965

Accumulated depreciation:		Land	Buildings and structures	Other equipment	Total
Balance as of January 1, 2022	\$	108,020	120,945	5,788	234,753
Depreciation (Note 1)		14,516	15,969	1,552	32,037
Disposals		(29,377)	(4,341)	(762)	(34,480)
Effect of change in foreign exchange rates		2,060	669	12	2,741
Balance as of March 31, 2022	<u></u>	95,219	133,242	6,590	235,051
Balance as of January 1, 2021	\$	60,596	82,963	6,916	150,475
Depreciation (Note 2)		10,594	15,702	1,301	27,597
Disposals		(382)	(1,667)	(910)	(2,959)
Effect of change in foreign exchange rates		(388)	(54)		(442)
Balance as of March 31, 2021	<u></u>	70,420	96,944	7,307	174,671
Carrying amount:	_				
Balance as of January 1, 2022	<u></u>	878,849	361,702	15,065	1,255,616
Balance as of March 31, 2022	\$	821,113	408,712	13,632	1,243,457
Balance as of January 1, 2021	\$	469,823	310,596	6,714	787,133
Balance as of March 31, 2021	\$	455,742	308,001	5,551	769,294

Note 1: Including capitalized depreciation expenses transferred to construction in progress, which amounted to \$46 thousand.

Note 2: Including capitalized depreciation expenses transferred to construction in progress, which amounted to \$1,843 thousand.

(k) Investment property

Cost:		Land	Buildings and structures	Total
Balance as of January 1, 2022	\$	963,127	138,225	1,101,352
Additions				
Balance as of March 31, 2022	<u>\$</u>	963,127	138,225	1,101,352
Balance as of January 1, 2021	\$	963,127	529,952	1,493,079
Additions		-	-	-
Reclassification as property, plant and equipment		-	(391,727)	(391,727)
Balance as of March 31, 2021	\$	963,127	138,225	1,101,352

		Land	Buildings and structures	Total
Accumulated depreciation:				
Balance as of January 1, 2022	\$	-	47,404	47,404
Depreciation		-	1,329	1,329
Balance as of March 31, 2022	\$		48,733	48,733
Balance as of January 1, 2021	\$	-	112,298	112,298
Depreciation		-	1,329	1,329
Reclassification as property, plant and equipment		-	(70,210)	(70,210)
Balance as of March 31, 2021	\$ <u></u>	-	43,417	43,417
Carrying amount:				
Balance as of January 1, 2022	\$	963,127	90,821	1,053,948
Balance as of March 31, 2022	\$	963,127	89,492	1,052,619
Balance as of January 1, 2021	\$	963,127	417,654	1,380,781
Balance as of March 31, 2021	\$	963,127	94,808	1,057,935
Fair value:				
Balance as of January 1, 2022			\$	1,183,495
Balance as of March 31, 2022			\$	1,179,601
Balance as of March 31, 2021			\$	1,201,648

When measuring the fair value of its investment property, the Group considered the present value of net cash flows to be generated from leasing the property. The expected net cash flows were discounted using the yield to reflect its specified inherit risk on the net cash flows. The inputs to the valuation technique used for measuring fair value were categorized as a Level 2 fair value. As of March 31, 2022, December 31 and March 31, 2021, the yield applied to the net annual rentals to determine fair value of property for which current prices in an active market were unavailable, was as follows:

	March 31,	December 31,	March 31,
Location	2022	2021	2021
Hsinchu	0.44%	0.42%	0.40%

As of March 31, 2022, December 31 and March 31, 2021, the investment properties were not pledged.

(l) Intangible assets

Carrying amount:		chnical ow-how	Computer software and information systems	Goodwill	Others	Total
Balance as of January 1, 2022	\$ <u></u>	44,318	284,449	312,405	713	641,885
Balance as of March 31, 2022	\$	41,895	261,886	316,342	257	620,380
Balance as of January 1, 2021	\$	8,775	285,763	277,404	6,489	578,431
Balance as of March 31, 2021	\$	7,622	305,149	277,653	4,492	594,916

There was no significant additions, disposals, or recognition and reversal of impairment losses of intangible assets for the three months ended March 31, 2022 and 2021. As of March 31, 2022, amortization of intangible assets was disclosed in Note 12(a). Other information was disclosed in Note 6(n) of the consolidated financial statements for the year ended December 31, 2021.

As of March 31, 2022, December 31 and March 31, 2021, the intangible assets were not pledged.

(m) Other current assets and other non-current assets

	-	March 31, 2022	December 31, 2021	March 31, 2021
Tax refund receivables	\$	143,744	125,031	97,106
Other receivables		35,090	23,700	22,447
Prepayments to suppliers		26,961	20,989	78,384
Prepaid expenses		118,965	138,001	90,899
Offset against business tax payable and input taxes		210,251	199,646	155,045
Restricted assets		280,186	118,900	168,490
Refundable deposits		153,036	160,040	165,334
Long-term prepayments to suppliers		36,074	36,074	-
Long-term prepaid intangible assets		2,672	2,672	54,797
Others		27,663	38,225	25,206
	<u></u>	1,034,642	863,278	857,708

(n) Short-term borrowings

	Ν	March 31, 2022	December 31, 2021	March 31, 2021
Secured short-term borrowings (in RMB)	\$	11,594		
Unused bank credit lines for short-term borrowings	\$	1,558,111	1,010,000	1,010,000
Unused bank credit lines for short-term and long-term borrowings	\$ <u></u>	4,090,400	3,568,680	4,098,900
Annual interest rate	=	3.75%		

The collateral for these short-term borrowings were disclosed in Note 8.

(o) Long-term borrowings

		March 31, 2022	December 31, 2021	March 31, 2021
Secured long-term borrowings (in TWD)	\$	-	750,000	750,000
Secured long-term syndicated borrowings (in USD)		5,718,842	5,522,160	4,673,425
Unsecured long-term borrowings (in TWD)		7,800,747	9,720,660	6,112,140
Less: long-term liabilities, current portion	_			
Total	\$	13,519,589	15,992,820	11,535,565
Unused bank credit lines for long-term borrowings	\$	15,453,368	8,922,568	11,070,128
Annual interest rate	=	0.50%~1.10%	0.25%~0.98%	0.25%~0.90%
Expiry date	1	2024/4/22~2029/1/20	2023/12/15~2025/8/16	2022/7/8~2025/8/16

As of March 31, 2022, the remaining balances of the borrowing due were as follows:

Year due	Amo	Amount		
April 1, 2023~March 31, 2024	\$	2,473,067		
April 1, 2024~March 31, 2025		4,577,680		
April 1, 2025~and after		6,468,842		
	\$	13,519,589		

(i) The unused bank credit lines for short-term and long-term borrowings at the reporting date were disclosed in Note 6(n).

(ii) The collateral for these long-term borrowings were disclosed in Note 8.

(iii) In June 2019, the Group entered into a three-year syndicated loan agreement with Far Eastern International Bank and other four banks. The total credit facility under this loan agreement is US\$200,000 thousand.

The related financial covenants and restrictions for the syndicated loans mentioned above were as follows:

- 1) At the end of reporting period, current ratio (current assets / current liabilities): shall not be lower than 100%;
- 2) Interest coverage ratio [(profit before tax + depreciation + amortization + interest expense) / interest expense)]: shall not be lower than 100%; and
- 3) Tangible net assets value (equity intangible assets): shall not be lower than NT\$15,000,000 thousand.

After the guarantor signs the loan agreement, the aforementioned financial ratio and criteria will be reviewed semi-annually, which are based on the year-end consolidated financial statements audited by the Certified Public Accountants (CPAs) that are approved by the leading bank, as well as the semi-annual consolidated financial statements reviewed by the CPAs.

For the year ended December 31, 2021 and for the six months ended June 30, 2021, the Group were in compliance with the above financial covenants and restrictions.

(iv) In December 2021, the Group entered into a three-year syndicated loan agreement with Far Eastern International Bank and other ten banks. The total credit facility under this loan agreement is US\$300,000 thousand. The loans from the initial withdrawal should be first paid off the outstanding amount of syndicated loan agreement in June 2019.

The related financial covenants and restrictions for the syndicated loans mentioned above were as follows:

- 1) At the end of reporting period, current ratio (current assets / current liabilities): shall not lower than 100%;
- 2) Interest coverage ratio [(profit before tax + depreciation + amortization + interest expense) / interest expense)]: shall not be lower than 100%; and
- 3) Tangible net assets value (equity intangible assets): hall not be lower than NT\$20,000,000 thousand.

After the guarantor signs the loan agreement, the aforementioned financial ratio and criteria will be reviewed semi-annually, which are based on the year-end consolidated financial statements audited by the Certified Public Accountants (CPAs) that are approved by the leading bank, as well as the semi-annual consolidated financial statements reviewed by the CPAs.

For the year ended December 31, 2021, the Group were in compliance with the above financial covenants and restrictions.

(p) Bonds payable

The details of bonds payable were as follows:

		March 31, 2022	December 31, 2021	l	March 31, 2021	
Overseas convertible bonds	\$	13,992,000	13,992,000		13,992,000	
Less: Unamortized discounted bonds payable		(662,710)	(705,361)		(832,498)	
Current portion	_				-	
Total	\$_	13,329,290	13,286,639		13,159,502	
Proceeds from issuance (less transaction cost amounted to \$89,226 thousand) \$ 13,902,774						
Equity components (less transaction cost amortized to equity component of \$4,147 (639,583						
thousand)						
Embedded derivatives instruments-put/ call o	ptic	ons			(139,920)	
Liability components at the issuance date (less	trar	nsaction cost all	ocated to liability	r	13,123,271	
component of \$85,079 thousand)						
Interest expense at an effective interest rate of	1.28	3%			206,019	
Liability components at March 31, 2022				\$	13,329,290	

The Company resolved to issue the first unsecured overseas convertible bonds, as proposed in the Board of Directors meeting held on November 27, 2020, which had been approved by the Financial Supervisory Commission with approval No.1090377907 on December 25, 2020 and been issued on the Singapore Exchange Securities Trading Limited on January 14, 2021. The Company issued the 5 years unsecured convertible bond, amounting to US\$500,000 thousand without coupon rate, with the maturity dates on January 14, 2026.

Unless previously redeemed, repurchased, and cancelled or converted, regulations and except during the closed period, the bonds may be converted into the Company's common shares pursuant to the applicable laws and regulations and the indenture at any time starting from the next day immediately after three months from the issue date to (1) the 10 day prior to the maturity date or (2) the 5 business day prior to the applicable redemption date on which a bondholder exercises its put right or the applicable date (other than the maturity date) on which the Company exercises its redemption right.

The conversion price was 140% of the closing price of the Company's common share on the Taipei Exchange on the pricing date, which was NT\$497. The number of common share to be delivered upon conversion of any bond will be determined with the principal amount of the bonds multiplied by the fixed exchange rate, which is NT\$27.984 to US\$1, which as determined on the pricing date and divided by the conversion price in effect on the date of conversion. After the issuance of the bonds, the conversion price shall be adjusted in accordance with the relevant anti-dilution provisions of the indenture. As of March 31, 2022, the conversion price was adjusted to NT\$483.16 per share.

The above-mentioned convertible bonds included liabilities and equity components. The equity component was accounted under the capital surplus-stock option. The effective interest rate originally recognized for the liability component was 1.28%.

(q) Lease liabilities

The carrying amounts of lease liabilities were as follow:

	N	March 31, 2022	December 31, 2021	March 31, 2021
Current	\$	123,352	122,882	89,108
Non-current	\$	1,030,059	1,034,327	595,501

For the maturity analysis, please refer to Note 6(aa).

The amounts recognized in profit or loss were as follows:

	mon	the three ths ended h 31, 2022	For the three months ended March 31, 2021
Interest expenses on lease liabilities	\$	6,962	4,998
Expenses relating to short-term leases	\$	1,630	3,650
Expenses relating to leases of low-value assets, excluding short-term leases of low-value assets	\$	396	350

The amounts recognized in the statement of cash flows for the Group was as follows:

	For the three	For the three
	months ended	months ended
	March 31, 2022	March 31, 2021
Total cash outflow for leases	\$42,469	36,077

(i) Real estate and buildings leases

The Group leases land and buildings and structures for its factories and staff dormitories. The leases of them typically run for a period of 2 to 50 years.

(ii) Other leases

The Group leases printer and transportation equipment, with lease terms of 2 to 10 years.

(iii) Others

Parts of the leases of transportation equipment, machinery and equipment, office and staff dormitories are with contract terms of less than one year. These leases are short-term. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases. Also, some leases contain cancellation options exercisable by the Group. In which lease is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(r) Operating lease

There were no significant changes in operating lease for the three months ended March 31, 2022 and 2021. Please refer to Note 6(t) of the consolidated financial statements for the year ended December 31, 2021 for other related information.

- (s) Employee benefits
 - (i) Defined benefit plans

At the end of the prior fiscal year, there was no material volatility of the market, no material reimbursement and settlement or other material one-time events. As a result, pension cost in the consolidated interim financial statements was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate as of December 31, 2021 and 2020.

The Group's expenses recognized in profit or loss were as follows:

		month	he three is ended 31, 2022	For the three months ended March 31, 2021
Operating costs		\$	-	-
Operating expenses			450	435
	1	\$	450	435

(ii) Defined contribution plans

The Group's expenses under the pension plan cost to the Bureau of Labor Insurance for the three months ended March 31, 2022 and 2021 were as follows:

	For the three months ended March 31, 2022	For the three months ended March 31, 2021
Operating costs	\$ 26,605	23,610
Operating expenses	7,169	7,045
	\$ 33,774	30,655

(iii) The Group's mainland China subsidiaries have a defined contribution plan. Monthly contributions to an independent fund administered by the government in accordance with the pension regulations in the People's Republic of China (PRC) are based on certain percentage of employees' monthly salaries and wages. Other than the monthly contributions, the Group has no further obligations. For the three months ended March 31, 2022 and 2021, the Group recognized the pension costs in accordance with the pension regulations and amounted to \$4,683 thousand and \$2,590 thousand, respectively.

(t) Income tax

(i) The amount of income tax expense was as follows:

	For the three	For the three
	months ended	months ended
	March 31, 2022	March 31, 2021
Income tax expense	\$204,704	291,334

- (ii) There was no income tax expense recognized in other comprehensive income for the three months ended March 31, 2022 and 2021.
- (iii) Assessment

The Company's corporate income tax returns for all the years through 2019 were assessed by the tax authorities.

(u) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the three months ended March 31, 2022 and 2021. For the related information, please refer to Note 6(w) of the consolidated financial statements for the year ended December 31, 2021.

(i) Ordinary shares

On March 18, 2021, the Company's Board of Directors approved a resolution to redeem the unvested restricted employee share of stock 15 thousand shares, at \$10 dollars par value per share, amounting to \$150 thousand. The recognition date for capital reduction was March 31, 2021. All related registration procedures had been completed.

(ii) Capital surplus

Balance of capital surplus at the reporting date were as follows:

	March 31,		December 31,	March 31,	
		2022	2021	2021	
Additional paid-in capital	\$	9,190,855	9,190,855	9,031,035	
Equity component of convertible bonds		639,583	639,583	639,583	
Changes in ownership interests in subsidiaries		85,565	85,565	69,410	
Changes in equity of associates accounted for					
using the equity method		1,419	510	-	
Employee stock options		3,245	3,245	3,163	
Restricted shares of stock issued for employee	s	50,156	50,156	219,888	
	<u></u>	9,970,823	9,969,914	9,963,079	

(iii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the balance of annual income or earnings after deducting accumulated deficit, if any, must be set aside as a legal reserve and a special capital reserve is likewise appropriated or the annual income or earnings are retained in accordance with the relevant laws or regulations or as requested by the authorities, but the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. Otherwise, the Company shall set aside at least 50% for shareholder, the distribution of remaining balance of the earnings should be further proposed by the Board of Directors and resolved by the shareholders' meeting. And the cash dividends should not lower than 10% of the total stockholders' dividends.

It is authorized the distributable dividends and bonuses or legal capital reserve and capital reserve in whole or in part may be paid in cash after a resolution has been adopted by a majority vote at a meeting of the Board of Directors attended by two-thirds of the total number of directors; and in addition thereto a report of such distribution shall be submitted to the shareholders' meeting.

As the Company is a technology and capital-intensive enterprise and is in its growth phase, it has adopted a more prudent approach in appropriating its remaining earnings as its dividend policy in order to sustain its long-term capital needs and thereby maintain continuous development and steady growth.

The appropriations of earning for 2021 and 2020 had been approved in the meeting of Board of Directors held on March 18, 2021 and 2020, respectively. The appropriations and dividends were as follows:

	 2021	2020
Cash dividends	\$ 3,391,811	4,240,414

The related information mentioned above can be found on websites such as the Market Observation Post System.

(iv) Other equity interests, net of tax

	difi tra forei	exchange Ferences on Inslation of gn financial atements	Unrealized gains (losses) on financial assets at fair value through other comprehensive income	Other unearned compensation for restricted shares of employees
Balance as of January 1, 2022	\$	(269,409)	1,044,071	(6,597)
Foreign currency differences (net of tax):				
The Group		319,011	-	-
Associates		69,744	-	-
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income (net of tax):				
The Group		-	(84,825)	-
Associates		-	579	-
Compensation cost arising from restricted shares of employees		-		4,398
Balance as of March 31, 2022	\$	119,346	959,825	(2,199)
	diff tra forei st	xchange erences on nslation of gn financial atements	Unrealized gains (losses) on financial assets at fair value through other comprehensive income	Other unearned compensation for restricted shares of employees
Balance as of January 1, 2021	\$	(202,205)	3,780,846	(65,738)
Foreign currency differences (net of tax):				
The Group		(37,152)	-	-
Associates		(5,733)	-	-
Unrealized gain (losses) from financial assets measured at fair value through other comprehensive income (net of tax)		-	38,864	-
Compensation cost arising from restricted				10.070
shares of employees	e	-	- 2.910.710	19,062
Balance as of March 31, 2021	<u>э</u>	(245,090)	3,819,710	(46,676)

(v) Share-based payment

Except for the following disclosure, there were no significant changes for share-based payment for the three months ended March 31, 2022 and 2021. For the related information, please refer to Note 6(x) of the consolidated financial statements for the year ended December 31, 2021.

(i) The Company issued restricted shares of stock for employee

On March 18 2021, the Company approved a resolution to redeem the unvested restricted employee share of stock amounting to 15 thousand shares. As of March 31, 2022 and 2021, there were 262 thousand and 1,375 thousand outstanding shares, respectively.

For the three months ended March 31, 2022 and 2021, the Company recognized the compensation cost of \$4,398 thousand and \$19,062 thousand for the aforementioned RSA, respectively.

(ii) The employee stock option (ESOPs) of subsidiary (PBL)

For the three months ended March 31, 2022 and 2021, the PBL recognized the compensation cost of \$0 thousand and \$421 thousand for the aforementioned ESOPs, respectively.

⁽w) Earnings per share ("EPS")

	For the three months ended <u>March 31, 2022</u>		For the three months ended March 31, 2021
Basic earnings per share:			
Profit belonging to common shareholders	\$	882,221	1,151,424
Weighted average number of outstanding shares of common stock (in thousands shares)	_	423,714	422,666
Basic earnings per share (in dollars)	\$	2.08	2.72
Diluted earnings per share:			
Profit belonging to common shareholders	\$	882,221	1,151,424
Weighted average number of outstanding shares of common stock (in thousands shares)		423,714	422,666
Effect of potentially dilutive common stock			
Employee remuneration (in thousands shares)		1,563	1,441
Restricted employee shares (in thousands shares)		255	1,258
Weighted-average number of common stock (diluted) (in thousands shares)		425,532	425,365
Diluted earnings per share (in dollars)	\$	2.07	2.71

For the three months ended March 31, 2022 and 2021, the convertible bonds have anti-diluted effects if the bonds were converted, and hence the convertible bonds were not included in the calculation of effect on potentially diluted common stock.

(x) Revenue from contracts with customers

(i) Disaggregation of revenue

	For the three months ended March 31, 2022						
		Segment- Foundry	Segment- Agriculture technology	Segment- Others (Note)	Total		
Primary geographical markets:							
Asia	\$	3,514,274	47,573	5,422	3,567,269		
Americas		1,503,112	-	8,746	1,511,858		
Taiwan		252,090	16	37,039	289,145		
Europe	_	229,003		(282)	228,721		
	<u></u>	5,498,479	47,589	50,925	5,596,993		
Main product/ services lines:	-						
Foundry	\$	5,498,479	-	-	5,498,479		
Others	_	-	47,589	50,925	98,514		
	\$	5,498,479	47,589	50,925	5,596,993		

		For the three months ended March 31, 2021						
		Segment- Foundry	Segment- Agriculture technology	Segment- Others	Total			
Primary geographical markets:								
Asia	\$	3,830,980	227,774	1,037	4,059,791			
Americas		1,455,083	-	7,660	1,462,743			
Taiwan		241,833	-	12,262	254,095			
Europe	_	232,754			232,754			
	<u></u>	5,760,650	227,774	20,959	6,009,383			
Main product/ services lines:	_							
Foundry	\$	5,760,650	-	-	5,760,650			
Others	_	-	227,774	20,959	248,733			
	<u></u>	5,760,650	227,774	20,959	6,009,383			

Note: Segment-others were mainly general investment businesses, and their net investment profits and losses were recognized as operating revenue.

(ii) Balance of contracts

	Ν	/Iarch 31, 2022	December 31, 2021	March 31, 2021	
Notes receivable	\$	965	1,053	606	
Accounts receivable		2,019,517	2,717,312	1,998,926	
Less: loss allowance		(798)	(805)	(99)	
	\$	2,019,684	2,717,560	1,999,433	
Contract liabilities	\$	249,011	353,157	507,395	

For details of notes and accounts receivable and allowance for impairment, please refer to Note 6(c).

The major change in the balance of contract liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received. The amount of revenue recognized for the three months ended March 31, 2022 and 2021, that was included in the contract liabilities balance at the beginning of the period was \$269,854 thousand and \$463,757 thousand, respectively.

(y) Employees' and directors' remuneration

According to the Company's Article of Incorporation, if there is any net profit after closing of a fiscal year, it shall be allocated according to the following principles:

- (i) Employees' remuneration: not less than 5% but no more than 10% and shall be determined and pursuant to Employee Bonus Procedure of the Company. In addition, employee's profitsharing remuneration shall be distributed in the form of shares or cash. Stock-type employee remuneration may be distributed to qualified employees of affiliates of the Company.
- (ii) Directors's remuneration: no more than 3%.

However, if there are any accumulated losses of the Company, the Company shall pre-reserve the amount to offset the loss. The distribution of employees' remuneration and directors's remuneration shall follow the special resolution by Board of Directors, and report it to the shareholders' meeting.

The Company estimated its employees' and directors' remuneration as follows:

		For the three months ended	
	March	31, 2022	March 31, 2021
Employees' remuneration	\$	77,000	102,700
Directors' remuneration		22,400	28,300
	\$	99,400	131,000

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration, and multiplied by the rule of Company's Article of Incorporation. The above remuneration was included in the operating costs and operating expenses of for the three months ended March 31, 2022 and 2021. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

For the years ended December 31, 2022 and 2021, the Company accrued and recognized its employees' remuneration amounting to \$447,000 thousand and \$543,300 thousand, and directors' remuneration amounting to \$129,000 thousand and \$157,700 thousand, respectively. There were no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements. The related information mentioned above can be found on websites such as the Market Observation Post System.

(z) Non-operating income and expenses

(i) Interest income

			For the three months ended	
	Marcl	n 31, 2022	March 31, 2021	
Interest income from bank deposits	\$	5,397	7,569	
Other interest income		17	32	
Interest income	\$	5,414	7,601	

(ii) Other income

	months ended		months ended		
	Marc	h 31, 2022	March 31, 2021		
Dividend income	\$	72,311	7,818		
Rent income		9,263	8,798		
Other income	\$	81,574	16,616		

For the three

For the three

(iii) Other gains and losses

		mo	r the three nths ended ·ch 31, 2022	For the three months ended 2 March 31, 2021
	Losses on disposals of property, plant and equipment	\$	(142	2) (5,428)
	Foreign exchange gains		338,919	9 191,273
	(Losses) gains on financial assets or liabilities at fair value through profit or loss		(279,040)) 77,992
	Losses on lease modification		(21,72	l) -
	Others		(31,414	<u>4) 10,536</u>
	Other gains and losses	\$	6,602	2 274,373
(iv)	Finance costs			
		mont	he three hs ended 1 31, 2022	For the three months ended March 31, 2021
	Interest expenses			
	Bank borrowings	\$	45,772	35,414
	Bonds payable		42,651	36,231
	Lease liabilities		7,008	6,516
	Less: capitalized interest		(14,966)	(9,617)
	Subtotal		80,465	68,544
	Other finance costs		36	38

(aa) Financial instruments

Finance costs

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information, please refer to Note 6(ac) of the consolidated financial statements for the year ended December 31, 2021.

(i) Credit risk

1) Credit risk of receivables and debt securities

For information on credit risk regarding notes and accounts receivable, please refers to Note 6(c).

68,582

80,501

\$

Other financial assets measured at amortized cost include other receivables. For related information of investment and impairment, please refers to Note 6(d).

All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited 12 months expected losses.

(ii) Liquidity risk

The following were the contractual maturities of financial liabilities:

	Carrying amount	Contractual cash flows	Within 1 year	1-2 years	2-5 years	Over 5 years
As of March 31, 2022						<u> </u>
Non-derivative financial liabilities						
Secured bank loans	\$ 5,730,436	5,891,895	58,933	47,016	5,785,946	-
Unsecured bank loans	7,800,747	7,946,195	59,892	2,524,734	4,983,194	378,375
Bonds payable	13,329,290	13,577,452	-	13,577,452	-	-
Accounts payable	1,530,971	1,530,971	1,530,971	-	-	-
Other payables	7,327,062	7,327,062	7,327,062	-	-	-
Guarantee deposits received	119,377	119,377	161	119,216	-	-
Lease liabilities	1,153,411	1,409,806	135,283	122,477	301,369	850,677
	\$ <u>36,991,294</u>	37,802,758	9,112,302	16,390,895	11,070,509	1,229,052
As of December 31, 2021						
Non-derivative financial liabilities						
Secured bank loans	\$ 6,272,160	6,420,797	40,043	189,481	6,191,273	-
Unsecured bank loans	9,720,660	9,864,259	60,610	2,659,255	7,144,394	-
Bonds payable	13,286,639	13,577,452	-	-	13,577,452	-
Notes and accounts payable	2,162,825	2,162,825	2,162,825	-	-	-
Other payables	3,440,833	3,440,833	3,440,833	-	-	-
Guarantee deposits received	130,398	130,398	11,951	8,447	110,000	-
Lease liabilities	1,157,209	1,429,386	134,132	119,574	300,119	875,561
	\$ <u>36,170,724</u>	37,025,950	5,850,394	2,976,757	27,323,238	875,561
As of March 31, 2021						
Non-derivative financial liabilities						
Secured bank loans	\$ 5,423,425	5,518,225	35,475	4,723,750	759,000	-
Unsecured bank loans	6,112,140	6,210,374	34,516	555,290	5,620,568	-
Bonds payable	13,159,502	13,577,452	-	-	13,577,452	-
Notes and accounts payable	1,943,421	1,943,421	1,943,421	-	-	-
Other payables	7,153,370	7,153,370	7,153,370	-	-	-
Guarantee deposits received	136,022	136,022	17,530	8,492	110,000	-
Lease liabilities	684,609	924,849	97,013	79,219	186,546	562,071
	<u>\$ 34,612,489</u>	35,463,713	9,281,325	5,366,751	20,253,566	562,071

The Group did not expect that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

(iii) Currency risk

1) Exposure to currency risk

The Group's significant exposure to foreign currency risk were as follows:

	March 31, 2022			December 31, 2021			March 31, 2021			
	_	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$	Foreign currency	Exchange rate	NT\$
Financial assets					<u>`</u>			`		
Monetary items										
USD	\$	368,383	28.63	10,546,806	453,406	27.68	12,550,289	719,672	28.54	20,539,427
EUR		2,701	31.92	86,219	57	31.32	1,775	1,460	33.48	48,882
JPY		1,646,794	0.2353	387,491	1,222,818	0.2405	294,088	1,306,358	0.2577	336,649
GBP		11	37.62	414	11	37.30	411	11	39.23	432
HKD		59	3.656	216	60	3.549	211	60	3.670	219
RMB		1,827	4.51	8,242	1,831	4.34	7,948	1,824	4.34	7,915
SGD		1	21.16	18	1	20.46	18	1	21.21	18
			5	<u>11,029,406</u>		\$	12,854,740		\$	20,933,542
Non-monetary items										
USD	\$	26,886	28.63	769,741	26,468	27.68	732,640	20,704	28.54	590,736
RMB		236,101	4.51	1,062,508	242,948	4.34	1,053,719	170,977	4.34	741,243
			5	5 1,832,249		5	1,786,359		\$	1,331,979
Financial liabilities										
Monetary items										
USD	\$	216,790	28.63	6,206,686	233,251	27.68	6,456,379	201,680	28.54	5,755,955
EUR		2,565	31.92	81,888	641	31.32	20,086	528	33.48	17,667
JPY		805,718	0.2353	189,585	982,177	0.2405	236,214	720,492	0.2577	185,671
			5	6,478,159		5	6,712,679		\$	5,959,293

2) Sensitivity analysis

The Group's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, notes and accounts receivable, other receivables, financial assets at fair value through profit or loss, notes and accounts payable, other payables, long-term borrowings, etc. that are denominated in foreign currency. A strengthening (weakening) 5 % of appreciation (depreciation) of the TWD against the USD, EUR, GBP, JPY, HKD, RMB, SGD, etc. for the three months ended March 31, 2022 and 2021 would have increased (decreased) the net profit after tax by \$212,844 thousand and \$622,734 thousand, respectively. The analysis assumes that all other variables remain constant.

3) Exchange gains or losses

Since the Group has many kinds of functional currency, the information on foreign exchange gains (losses) on monetary items is disclosed by total amount. For three months ended March 31, 2022 and 2021, foreign exchange gains (including realized and unrealized portions) amounted to \$338,919 thousand and \$191,273 thousand, respectively.

(iv) Interest rate risk

Please refer to the attached note for the liquidity risk and the Group's interest rate exposure to its financial liabilities.

The following sensitivity analysis is based on the risk exposure to interest rates on the nonderivatives financial instruments on the reporting date. For variable rate instruments, the sensitivity analysis assumes the variable rate liabilities are outstanding for the whole year on the reporting date.

If the interest rate increases (decreases) by 0.5%, the Group's net profit after tax would have increased (decreased) by \$14,561 thousand and \$11,793 thousand for the three months ended March 31, 2022 and 2021, respectively, all other variable factors that remain constant. This is mainly due to the Group's borrowing in floating rates.

- (v) Fair value
 - 1) Financial instrument classifications and fair values

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income are measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities disclosure of fair value information is not required.

		March 31, 2022							
				Fair					
	Car	rying value	Level 1	Level 2	Level 3	Total			
Financial assets at fair value through profit or loss									
Stocks listed on domestic markets	\$	14,197	14,197	-	-	14,197			
Non-public stocks		398,433	-	-	398,433	398,433			
Funds and investment		42,360	42,360	-	-	42,360			
Private fund		1,542,726		-	1,542,726	1,542,726			
Subtotal	\$	1,997,716	56,557	-	1,941,159	1,997,716			
Financial assets at fair value through other comprehensive	income								
Stocks listed on domestic and foreign markets	\$	1,445,713	1,445,713	-	-	1,445,713			
Non-public stocks		651,391		-	651,391	651,391			
Subtotal	\$	2,097,104	1,445,713	-	651,391	2,097,104			

Financial assets measured at amortized cost Cash and cash equivalents (Note)	<u>Ca</u> \$	rrying value	Level 1	Fair v Level 2	Zalue Level 3	
Cash and cash equivalents (Note)					Level 5	Total
	\$					
		14,207,296	-	-	-	-
Notes and accounts receivable (Note)		2,019,684	-	-	-	-
Other receivables (Note)		35,090	-	-	-	-
Other non-current assets (Note)		433,222	-	-		
Subtotal	\$	16,695,292	-	-		
Financial liabilities at fair value through profit or loss						
Derivative financial liabilities	\$	526,099	-	526,099		526,099
Financial liabilities measured at amortized cost						
Bank loans (Note)	\$	13,531,183	-	-	-	-
Bonds payable (Note)		13,329,290	-	-	-	-
Accounts payable (Note)		1,530,971	-	-	-	-
Other payables (Note)		7,327,062	-	-	-	-
Guarantee deposits received (Note)		119,377	-	-	-	-
Lease liabilities (Note)		1,153,411	-	-	-	-
Subtotal	\$	36,991,294		-		
	=		:			
			De	cember 31, 2021		
	Ca	rrying value	Level 1	Fair v Level 2	Level 3	Total
Financial assets at fair value through profit or loss		<u> </u>				
Stocks listed on domestic markets	\$	18,541	18,541	-	-	18,541
Non-public stocks		380,417	-	-	380,417	380,417
Funds and investment		43,334	43,334	-	-	43,334
Private fund		1,442,016		-	1,442,016	1,442,016
Subtotal	\$	1,884,308	61,875	-	1,822,433	1,884,308
Financial assets at fair value through other comprehensive incor	ne	<u> </u>				
Stocks listed on domestic and foreign markets	\$	1,506,235	1,506,235	-	-	1,506,235
Non-public stocks		680,342	-	-	680,342	680,342
Subtotal	\$	2,186,577	1,506,235	-	680,342	2,186,577
Financial assets measured at amortized cost						
Cash and cash equivalents (Note)	\$	16,331,759	-	-	-	-
Notes and accounts receivable (Note)		2,717,560	-	-	-	-
Other receivables (Note)		23,700	-	-	-	-
Other non-current assets (Note)		278,940	-	-	-	-
Subtotal	\$	19,351,959	-	-		
Financial liabilities at fair value through profit or loss	=					
Derivative financial liabilities	\$	180,497	_	180,497	-	180,497
Financial liabilities measured at amortized cost	Ĩ		:			
Bank loans (Note)	\$	15,992,820	_	_	-	_
Bonds payable (Note)	Ŷ	13,286,639	_	_	-	_
Notes and accounts payable (Note)		2,162,825	_	_	-	_
Other payables (Note)		3,440,833	-	-	-	_
Guarantee deposits received (Note)		130,398	-	-	-	-
Lease liabilities (Note)			-	-	-	-
Subtotal	e	1,157,209				
Subtrat	°	36,170,724		-		

(Continued)

			Ν	larch 31, 2021		
	~			Fair v		
Financial assets at fair value through profit or loss	Ca	rrying value	Level 1	Level 2	Level 3	Total
Stocks listed on domestic markets	\$	19,292	19,292			19,292
Funds and investment	Φ	876,289	876,289	-	-	876,289
Private fund		969,440	870,289	-	- 969,440	969,440
Subtotal						
	\$	1,865,021	895,581	-	969,440	1,865,021
Financial assets at fair value through other comprehensive in						
Stocks listed on domestic and foreign markets	\$	5,747,455	5,747,455	-	-	5,747,455
Non-public stocks		1,011,117		-	1,011,117	1,011,117
Subtotal	\$ <u></u>	6,758,572	5,747,455	-	1,011,117	6,758,572
Financial assets measured at amortized cost						
Cash and cash equivalents (Note)	\$	22,333,515	-	-	-	-
Notes and accounts receivable (Note)		1,999,433	-	-	-	-
Other receivables (Note)		22,447	-	-	-	-
Other non-current assets (Note)		333,824		-		-
Subtotal	\$	24,689,219		-		-
Financial liabilities at fair value through profit or loss						
Derivative financial liabilities	\$ <u></u>	190,291		190,291		190,291
Financial liabilities measured at amortized cost						
Bank loans (Note)	\$	11,535,565	-	-	-	-
Bonds payable (Note)		13,159,502	-	-	-	-
Notes and accounts payable (Note)		1,943,421	-	-	-	-
Other payables (Note)		7,153,370	-	-	-	-
Guarantee deposits received (Note)		136,022	-	-	-	-
Lease liabilities (Note)		684,609		-		-
Subtotal	\$	34,612,489		-		-

Note: The information on fair value is not disclosed since the carrying amount is a reasonable approximation of fair value.

2) Valuation techniques of financial instrument not valued at fair value

The valuation techniques of the Group's financial instruments not valued at fair value by using the methods and assumptions are as follows:

• Financial assets measured at amortized cost and financial liabilities measured at amortized cost.

If recent transaction prices or market maker quotes are available, the fair value is based on such information. If there is no quoted market price available, the fair value is determined by using valuation techniques and calculated as the present value of the estimated cash flows.

- 3) Valuation techniques of financial instruments valued at fair value
 - a) Non-derivative instruments

The fair value of financial assets and liabilities traded in an active market is based on the quoted market prices. The quotation, which is published by the main exchange center or that which was deemed to be a public bond by the Treasury Bureau of Central Bank, is included in the fair value of the listed securities instruments and the debt instruments in active markets with open bid.

A financial instrument is regarded as the quoted price in an active market if the quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency; and if those prices represent the actual and regularly occurring market transactions on an arm's length basis. Otherwise, the market is deemed to be inactive. Normally, a market is considered to be inactive when:

- The bid-ask spread is increasing; or
- The bid-ask spread varies significantly; or
- There has been a significant decline in trading volume.

When the financial instrument of the Group is traded in an active market, its fair value is illustrated by the category and nature as follows:

- Financial assets and liabilities with standard terms and conditions and traded in an active market, for example, investment in stock of listed companies: the fair value is based on the market quoted price.
- Close-end funds with standard terms and conditions, such as money market funds; investors can require the investment trust company to redeem the fund at any time. The fair value is based on the net value of the fund.

Except for the above-mentioned financial instruments traded in an active market, the fair value is based on the valuation techniques or the quotation from the counter-party. The fair value refers to the current fair value of the other financial instruments with similar conditions and characteristics, using a discounted cash flow analysis or other valuation techniques, such as calculations of using models (for example, applicable yield curve from Taipei Exchange, or average quoted price on interest rate of commercial paper from Reuters), based on the information acquired from the market at the balance sheet date.

When the financial instrument of the Group is not traded in an active market, its fair value is determined as follows:

- The fair value is determined based on the ratio of the quoted market price of the comparative listed company and its book value per share and its sales revenue per share. Also, the fair value is discounted for its lack of liquidity in the market.
- The fair value is determined by using the asset-based approach, whose assumptions are based on the market approach, income approach, cost approach or other valuation methods according to the nature of the assets or liabilities of the subject companies.
- b) Derivative instruments

The fair value is determined by using the models that are acceptable to the market participants, for example, discounted cash flow analyses or option pricing models. Forward exchange contracts are measured using quoted forward exchange rates. The fair value of structured interest derivative financial instruments is determined by using the proper option pricing models, such as Black-Scholes model, or other valuation technique, such as Monte Carlo simulation.

4) Transfer between level 2 and level 1

For three months ended March 31, 2022 and 2021, there was no transfer between level 2 and level 1 financial asset of the fair value hierarchy.

5) Movement of level 3

	ŀ	air value throug	h profit or loss	Fair value through other comprehensive income
		Unquoted equity instruments	Private fund	Unquoted equity instruments
Balance as of January 1, 2022	\$	380,417	1,442,016	680,342
Total gains or losses:				
Recognized in profit and loss		4,927	60,937	-
Recognized in other comprehensive income		-	-	(23,234)
Purchased		-	45,162	-
Capital reduction		-	(5,389)	(6,667)
Effect of changes in foreign exchange rates	_	13,089		950
Balance as of March 31, 2022	\$_	398,433	1,542,726	651,391

	ŀ	Fair value throus Unquoted	gh profit or loss	Fair value through other comprehensive income Unquoted
		equity		equity
	_	instruments	Private fund	instruments
Balance as of January 1, 2021	\$	-	814,065	963,298
Total gains or losses:				
Recognized in profit and loss		-	119,310	-
Recognized in other comprehensive income		-	-	47,759
Purchased		-	36,966	-
Capital reduction		-	(901)	-
Effect of changes in foreign exchange rates	_	-		60
Balance as of March 31, 2021	\$_	-	969,440	1,011,117

The preceding gains and losses were recognized as "other gains and losses" and "unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income". As of March 31, 2022 and 2021, the related information of the assets which were still held by the Group were as follows:

	For the three months ended March 31, 2022		months ended	
Total gains or losses				
Profit or loss (recognized as other gains and losses)	\$	65,864	119,310	
Other comprehensive income (recognized as unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive				
income)		(23,234)	47,759	

6) Quantified information on significant unobservable inputs (Level 3) used in fair value measurement

The Group's financial instruments that use Level 3 inputs to measure fair value include "financial assets at fair value through profit or loss – equity investment", "financial assets at fair value through profit or loss – private funds" and "financial assets at fair value through other comprehensive income – equity investments."

Most of the fair value measurements categorized within Level 3 use the single and significant unobservable input. Equity investments without an active market contains multiple significant unobservable inputs. The significant unobservable inputs of the equity investments are independent from each other, as a result, there is no relevance between them.

Quantified information of significant unobservable inputs was as follows:

Item	Valuation technique	Significant unobservable inputs	Inter-relationship between significant unobservable inputs and fair value measurement
Financial assets at fair value through other comprehensive income – equity investments without an active market	Comparable listed companies approach	 Price-book ratio (as of March 31, 2022, December 31 and March 31, 2021 were 1.71~4.77, 1.66~6.27 and 1.78~7.90, respectively) Market liquidity discount rate (as of March 31, 2022, December 31 and March 31, 2021 were both 20%) 	 The higher the price- book ratio, the higher the fair value The higher the market liquidity discount rate, the lower the fair value
	• Net asset value method	• Net asset value	• The higher the net assets value, the higher the fair value
Financial assets at fair value through profit or loss – equity investments without an active market	Comparable listed companies approach	 Price-to-sale ratio (as of March 31, 2022 and December 31, 2021 were 6.30 and 5.97, respectively.) Market liquidity discount rate (as of March 31, 2022 and December 31, 2021 were both 20%) 	 The higher the price-to sales ratio, the higher the fair value The higher the market liquidity discount rate, the lower the fair value
Financial assets at fair value through profit or loss – private fund	• Net asset value method	• Net asset value	• The higher the net assets value, the higher the fair value

7) Sensitivity analysis of reasonably possible alternative assumptions for fair value measurements in Level 3 of the fair value hierarchy

The fair value measurements of the Group's financial instruments are reasonable. However, changes in the use of valuation models or valuation variables may affect the estimations. For fair value measurements in Level 3, a fluctuation in the valuation variable by 5% would have the following effect:

			_		anges in fair cofit or loss	Effects of changes in fair value on other comprehensive income	
March 31, 2022	Inputs	Increase or decrease		Favorable	<u>Unfavorable</u>	Favorable	<u>Unfavorable</u>
Financial assets at fair value through profit or loss							
Equity investments without an active market	Price-to-sales ratio	5%	\$	19,922	(19,922)	-	-
11	Market liquidity discount rate	5%		19,922	(19,922)	-	-
Private fund	Net asset value	5%		77,136	(77,136)	-	-

				Effects of ch value on p	aanges in fair rofit or loss	Effects of changes in fair value on other comprehensive income		
	Inputs	Increase or decrease		Favorable	Unfavorable	Favorable	Unfavorable	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%	\$	-	-	12,517	(12,517)	
//	Market liquidity discount rate	5%		-	-	12,517	(12,517)	
11	Net asset value	5%		-	-	20,052	(20,052)	
December 31, 2021								
Financial assets at fair value through profit or loss								
Equity investments without an active market	Price-to-sales ratio	5%	\$	19,021	(19,021)	-	-	
"	Market liquidity discount rate	5%		19,021	(19,021)	-	-	
Private fund	Net asset value	5%		72,101	(72,101)	-	-	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%		-	-	13,944	(13,944)	
//	Market liquidity discount rate	5%		-	-	13,944	(13,944)	
11	Net asset value	5%		-	-	20,073	(20,073)	
March 31, 2021								
Financial assets at fair value through profit or loss								
Private fund	Net asset value	5%	\$	48,472	(48,472)	-	-	
Financial assets at fair value through other comprehensive income								
Equity investments without an active market	Price-book ratio	5%		-	-	29,682	(29,682)	
"	Market liquidity discount rate	5%		-	-	29,682	(29,682)	
//	Net asset value	5%		-	-	20,874	(20,874)	

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the inter-relationships with another input.

(ab) Management of financial risk

There was no significant change in the Group's objective and policies for the management of financial risk of the consolidated financial statements for the three months ended March 31, 2022 which compared with the consolidated financial statements Note 6(ad) for the year ended December 31, 2021.

(ac) Capital management

The Group's objective, policies and process of capital management of the consolidated financial statements for the three months ended March 31, 2022 was the same as the consolidated financial statements for the year ended December 31, 2021. For the related information, please refer to Note 6(ae) of the consolidated financial statements for the year ended December 31, 2021.

As of March 31, 2022, December 31 and March 31, 2021, the Group's return on common equity was 10.43%, 15.81% and 14.02%, respectively. The Group's debt ratio at the reporting date were as follows:

	March 31,	December 31,	March 31,
	2022	2021	2021
Debt ratio	52.89 %	50.43 %	52.63 %

(ad) Financing activity

Reconciliations of liabilities arising from financing activities were as follows:

				Cash flows		No	n-cash chang	es	
	Jan	uary 1, 2022	Proceeds from long- term debt and bonds payable	Repayments of long-term debt and lease liabilities	Others	Interest expense	Others	Amortization of arranger fee of syndicated loan	March 31, 2022
Short-term borrowings	\$	-	11,594	-	-	-	-	-	11,594
Long-term borrowings		15,992,820	1,453,200	(4,123,113)	-	-	189,683	6,999	13,519,589
Bonds payable		13,286,639	-	-	-	42,651	-	-	13,329,290
Guarantee deposit received	l	130,398	-	-	(11,021)	-	-	-	119,377
Lease liabilities (Note 1)		1,157,209	-	(27,389)	(13,054)	7,008	29,637		1,153,411
Total liabilities from financing activity	\$	30,567,066	1,464,794	(4,150,502)	(24,075)	49,659	219,320	6,999	28,133,261
				Cash flows		No	n-cash change		
	Jan	uary 1, 2021	Proceeds from long- term debt	Repayments of long-term debt and lease liabilities	Others	Interest expense	Others	Amortization of arranger fee of syndicated loan	March 31, 2021
Long-term borrowings	\$	11,418,620	1,653,750	(1,558,000)	-	-	14,103	7,092	11,535,565
Bonds payable		-	13,902,774	-	-	36,231	(779,503)) -	13,159,502
Guarantee deposit received	l	124,732	-	-	11,290	-	-	-	136,022
Lease liabilities (Note 2)		699,884		(29,665)	(2,412)	6,516	10,286		684,609
Total liabilities from financing activity	\$	12,243,236	15,556,524	(1,587,665)	8,878	42,747	(755,114)	7,092	25,515,698

Note 1: Interest expense includes capitalized interest expense transferred to construction in progress, which amounted to \$46 thousand. Note 2: Interest expense includes capitalized interest expense transferred to construction in progress, which amounted to \$1,518 thousand.

(7) Related-party transactions:

(a) Names and relationship with related parties

The followings are entities that have had transactions with related party during the periods covered in the consolidated financial statements:

Name of related party	Relationship with the Group
Jiangsu CM/Chainwin Agriculture Development Co., Ltd. (abbrev.	Associates
Jiangsu CM/Chainwin)	
ITEQ Corporation (abbrev. ITEQ) (Note)	Associates
Chainwin i-Management (Huaian) Co., Ltd.	Other related parties
Taoyuan i-Fare Charity Foundation	Other related parties

Note: In July 2021, the Group has significant influence over ITEQ, and therefore the ITEQ has become the Group's associates since July 2021.

(b) Significant transactions with related parties

(i) Purchases

The amounts of significant purchases by the Group from related parties were as follows:

	For the three	For the three
	months ended	months ended
	March 31, 2022	March 31, 2021
Other related parties	\$ <u> </u>	1,618

The terms and pricing of purchase transactions with related parties were not significantly different from those offered by other vendors.

(ii) Payables to Related Parties

The payables to related parties were as follows:

Account	Categories	March 31, 2022	December 31, 2021	March 31, 2021
Accounts payable	Other related parties	\$ <u> </u>	-	59

(iii) Operating expenses

The amounts of operating expenses by the Group from related parties were as follows:

	For the three	For the three
	months ended	months ended
	March 31, 2022	March 31, 2021
Other related parties	\$ <u> </u>	4,000

(iv) Guarantee

As of March 31, 2022, December 31, and March 31, 2021, Chainwin Cayman had provided a guarantee for loans amounting to US\$7,350 thousand (\$210,431 thousand, \$203,448 thousand and \$209,769 thousand, respectively) to its associate, Jiangsu CM/Chainwin.

(v) Property transactions – acquire assets

			For the three months ended
Account	Category	March 31, 2022	March 31, 2021
Property, plant and equipment	Other related parties	\$ <u> </u>	93

(vi) Leases

The Group leased the office and factories to its associate, ITEQ, and the rent income received monthly is based on the nearby office and factories rental rates. The amount of rent income is \$7,376 thousand and \$7,231 thousand for the three months ended March 31, 2022 and 2021. The preceding rent payment has been received. The guarantee deposits received amounted to \$110,000 thousand as of March 31, 2022, December 31, and March 31, 2021.

(c) Transactions with key management personnel

Key management personnel compensation was comprised as below:

	I		For the three months ended March 31, 2021
Short-term employee benefits	<u>1</u> \$	108,390	
Post-employment benefits	¢	315	<u> </u>
	D	108,705	181,957

(8) Pledged assets:

The carrying amounts of pledged assets were as follows:

Pledged assets	Pledged to secure		March 31, 2022	December 31, 2021	March 31, 2021
Other non-current assets	Land, plant, and dormitory lease guarantee	\$	35,438	35,043	35,050
Other non-current assets	Bank deposits-reserve accounts		155,643	9,310	7,848
Other non-current assets	Gas deposits		4,700	4,700	4,700
Other non-current assets	Customs guarantee with interest		20,579	20,579	20,430
Other non-current assets	Guarantee deposits of letters of credit		31,012	44,056	75,572
Other non-current assets	Seized funds and court security deposits		32,814	5,212	24,890
Property, plant and	Long-term borrowings				
equipment		_	2,221,763	2,244,061	2,303,481
Total		\$	2,501,949	2,362,961	2,471,971

54

(Continued)

(9) Commitments and contingencies:

- (a) Contingencies: None.
- (b) Commitment:
 - (i) The unrecognized commitment of acquisition of plant expansion and machinery equipment was as follows:

	March 31,		December 31,	March 31,
	2022		2021	2021
The unrecognized amount	\$	9,763,107	7,431,148	5,247,061

(ii) The unused letters of credit was as follows:

	Μ	arch 31, 2022	December 31, 2021	March 31, 2021
The unused letters of credit	\$	40,360	43,956	2,600

(10) Losses due to major disasters: None.

(11) Subsequent events: None.

(12) Other:

(a) The followings were the summary statement of employee benefits, depreciation and amortization expenses by function:

	For the three	e months ended 2022	March 31,	For the three months ended March 31, 2021						
	Classified as operating costs	as operating as operating Total a		Classified as operating costs	Classified as operating expenses	Total				
Employee benefits										
Salaries	709,459	286,667	996,126	742,276	358,334	1,100,610				
Labor and health insurance	75,609	22,457	98,066	62,610	19,115	81,725				
Pension	28,042	10,865	38,907	24,195	9,485	33,680				
Director remuneration	-	22,452	22,452	-	28,357	28,357				
Others	30,583	11,664	42,247	36,042	15,663	51,705				
Depreciation	939,151	118,625	1,057,776	897,795	101,748	999,543				
Amortization	8,388	27,940	36,328	7,932	23,475	31,407				

(b) Seasonality of operations:

The Group's operations were not affected by seasonality or cyclicality factors.

(c) As of the date the financial statements were authorized for issurance, the COVID-19 pandemic did not have a significant impact on the Group's operating ability, and the Group is continuously monitoring and assessing the situation.

(13) Other disclosures:

(a) Information on significant transactions:

The following were the information on significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the Group for the three months ended March 31, 2022:

- (i) Loans to other parties: Please refer to schedule A.
- (ii) Guarantees and endorsements for other parties: Please refer to schedule B.
- (iii) Securities held as of March 31, 2022 (excluding investment in subsidiaries, associates and joint ventures): Please refer to schedule C.
- (iv) Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule D.
- (v) Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: Please refer to schedule E.
- (vi) Information on disposal of real estate with amounts exceeding the lower of NT\$300 million or 20% of the Company's paid-in capital: None.
- (vii) Information regarding related-parties purchases and/or sales with amounts exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: None.
- (viii) Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital: Please refer to schedule F.
- (ix) Information regarding trading in derivative financial instruments: Please refer to Note 6(b).
- (x) Business relationships and significant intercompany transactions: Please refer to schedule G.
- (b) Information on investments: Please refer to schedule H.
- (c) Information on investment in mainland China: Please refer to schedule I.
- (d) Information on major shareholders: Please refer to schedule J.

(14) Segment information:

(a) The Group's reportable segment is the foundry segment, and agriculture technology segment. The segment engages separately in researching, developing, manufacturing, selling of GaAs wafers and developing hog farming technology and trading, etc., respectively.

Other operating segments are mainly engaged in investment activities and gene chip and testing, which do not exceed the quantitative thresholds to be reported.

(b) Operating segment profit or loss (includes reportable segment revenue and expenses), segment assets, segment liabilities, and their measurement and reconciliations for the three months ended March 31, 2022 and 2021, the reportable amount is same as that in the report used by the operating decision maker and the operating segment accounting policies are same as the ones described in Note 4 "significant accounting policies" were as follows:

For the three months ended March 31, 2022	2	Foundry	Agriculture technology	l Others	Reconciliation and elimination	Total
Revenue:		- 400 4-0				
Revenue from external customers	\$_	5,498,479	47,589	50,925		5,596,993
Interest expenses	\$_	51,391	27,426	1,684		80,501
Depreciation and amortization	\$	998,583	87,222	8,299		1,094,104
Share of profit (loss) of associates and joint ventures accounted for using equity	_					
method	\$_	95,148	(33,693)	20,423	_	81,878
Reportable segment profit or loss	\$	1,254,271	(326,523)	(11,530)	_	916,218
Assets:	_					
Capital expenditures in noncurrent assets	\$	658,312	677,451	2,546		1,338,309
For the three months ended March 31, 2021 Foundry			Agriculture technology_	Others	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$	5,760,650	227,774	20,959		6,009,383
Interest expenses	\$	45,261	21,575	1,746		68,582
Depreciation and amortization	\$	992,336	31,045	6,595	974	1,030,950
Share of loss of associates and joint ventures accounted for using equity method	\$	-	(39,064)	(282)		(39,346)
Reportable segment profit or loss	\$	1,314,666	(87,938)	(30,208)	(974)	1,195,546
Assets:	=					
Capital expenditures in noncurrent assets	\$	666,017	1,150,936	46,498		1,863,451

For the three months ended March 31, 2022 and 2021, reportable segment profit or loss excludes non-operating income and expenses, amounting to \$74,544 thousand and \$190,944 thousand, respectively.

Schedule A Loans to other parties:

(In thousands of Dollars)

Number (Note 1)	Name of lender	Name of borrower	Account name	Related party	Highest balance of financing to other parties during the period (Note 2)		Actual amount drawn down	Interest Rate	Purposes of fund financing for the borrower	Transaction amount	Reasons for short- term financing	Allowance for bad debts	Coll	ateral	Individual funding loan limits (Note 4) (Note 5)	Maximum limit of fund financing (Note 4) (Note 5)	Remark
					1 ()				(Note 3)		5		Item	Value			
1	Chainwin Biotech and Agrotech	Jiangsu Chainwin Kang Yuan	Other receivables	Y	1,002,050	572,600	-	1%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 7)
	(Cayman Islands) Co., Ltd.	Agricultural Development Co., Ltd.			(USD 35,000	(USD 20,000)					Capital				2,128,340	4,256,681	
1	Chainwin Biotech and Agrotech	Jiangsu Win Yield Agriculture	Other receivables	Y	572,600	572,600	114,520	1%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 7)
	(Cayman Islands) Co., Ltd.	Development Co., Ltd.			(USD 20,000	(USD 20,000)	(USD 4,000)				Capital				2,128,340	4,256,681	
2	Phalanx Biotech Group, Inc.	PhalanxBio, Inc.	Other receivables	Y	286	286	-	4%	2	-	Working	-	None	-	Net equity 20%=	Net equity 40%=	(Note 7)
					(USD 10	(USD 10)					Capital				128,621	257,243	1

Note 1: Company numbering as follows:

Issuer-0

Investee starts from 1

Note 2: The credit amount to lending.

Note 3: Purposes of lending were as follows:

1. Business relationship

2. Short-term financing

Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of financing to other parties:

1. The loan limit to an individual party:(1) the total amount for lending to a company having business relationship with Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher). (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. 's equity based on its most recent audited or reviewed financial statements by a certified accountant.

2. The maximum loans to other parties limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant.

Note 5: Phalanx Biotech Group, Inc.'s operating procedures of financing to other parties:

1. The loan limit to an individual party : (1) the total amount for lending to a company having business relationship with Phalanx Biotech Group, Inc. shall not exceed their previous or current's total purchasing or sales amount (whichever is higher). (2) the total amount for lending to a company having short-term funding needs shall not exceed 20% of Phalanx Biotech Group, Inc.'s equity based on its most recent audited or reviewed financial statements by a certified accountant.

2. The maximum loans to other parties provided by Phalanx Biotech Group, Inc. should not exceed 40% of its equity based on its most recent audited or reviewed financial statements by a certified accountant

Note 6: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to NTD 28.63.

Note 7: The amount of the transaction had been offset in the consolidated financial statements.

Schedule B Guarantees and endorsements for other parties:

												(In thous	ands of Dollars)
Number (Note 1)	Name of guarantor	Counter-party of guarantee and endorser	Relationship with the Company (Note 2)	Limitation on amount of guarantees and endorsements for a specific enterprise (Note 3)(Note 4)	Highest balance of guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 3)(Note 4)	Parent company endorsements/ guarantees to subsidiary (Note 6)	Subsidiary endorsements/ guarantees to parent company (Note 6)	Endorsements/ guarantees to the companies in mainland China (Note 6)
0	The Company	Chainwin Biotech and Agrotech (Cayman	2	16,369,313	2,385,824	2,385,824	286,300	-	7.29%	Net equity 50%=	Y	-	-
		Islands) Co., Ltd.								16,369,313			
0	//	Jiangsu Chainwin Kang Yuan Agricultural	2	16,369,313	3,244,724	3,244,724	1,717,800	-	9.91%	Net equity 50%=	Y	-	Y
		Development Co., Ltd.								16,369,313			
0	"	Jiangsu Win Yield Agriculture Development	2	16,369,313	4,676,252	4,676,252	2,576,700	-	14.28%	Net equity 50%=	Y	-	Y
		Co., Ltd.								16,369,313			v
0	"	Jiangsu Win Shine Agriculture Development	2	16,369,313	-	-	-	-	0.00%	Net equity 50%=	Y	-	Y
0		Co., Ltd.	2	16,369,313	2,099,524	2,099,524	1,145,200		6.41%	16,369,313 Net equity 50%=	v		v
0	"	Jiangsu Chainwin Agriculture and Animal Technology Co., Ltd.	2	10,309,313	2,099,524	2,099,524	1,145,200	-	0.41%	16,369,313	Ŷ	-	Ŷ
0	"	Jiangsu Win Chance Agriculture	2	16,369,313	-	-	-	-	0.00%	Net equity 50%=	Y	-	Y
		Development Co., Ltd.	_							16,369,313			
0	//	Jiangsu Win Fortune AgricIture	2	16,369,313	763,476	763,476	-	-	2.33%	Net equity 50%=	Y	-	Y
		Development Co., Ltd.								16,369,313			
0	"	Jiangsu Win Boutique Agriculture	2	16,369,313	572,600	572,600	-	-	1.75%	Net equity 50%=	Y	-	Y
		Development Co. Ltd.								16,369,313			
0	//	Jiangsu Win Sunlight Agriculture	2	16,369,313	572,600	572,600	-	-	1.75%	Net equity 50%=	Y	-	Y
		Development Co. Ltd.								16,369,313			
1	Chainwin Biotech and Agrotech	Jiangsu CM/Chainwin Agriculture	6	3,192,511	210,431	210,431	-	-	1.98%	Net equity 50%=	-	-	Y
	(Cayman Islands) Co., Ltd.	Development Co., Ltd.		(USD 111,509)		(USD 7,350)				5,320,851			1
1	"	Jiangsu Chainwin Kang Yuan Agricultural	2	3,192,511	128,835	128,835	11,594	143,150	1.21%		-	-	Y
		Development Co., Ltd.	1	(USD 111,509)	(USD 4,500)	(USD 4,500)	(RMB 2,573)	(USD 5,000)		5,320,851			

Note 1: Company numbering as follows:

1. Issuer – 0

2. Investee starts from 1

Note 2: The 7 types of relationship between the guarantee and the guarantor were as follows:

1. For entities the guarantor has business transaction with.

2. For entities in which the guarantor, directly or indirectly, owned more than 50% of their shares.

3. For entities who owned, directly or indirectly, more than 50% in total of the guarantor's shares.

4. For entities in which the guarantor, directly or indirectly, owned more than 90% of their shares.

5. Fulfillment of contractual obligation by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.

6. For entities who are guaranteed and endorsed by all capital contributing shareholders in proportion to each of their shareholder's percentage.

7. Performance guarantee in which entities within the same industry provide among themselves joint and several securities by entering into sales agreement with each other for pre-construction project pursuant to Company Protection Act.

Note 3: WIN Semiconductors Corp.'s operating procedures of guarantee and endorsement were as follows:

1. The guarantees and endorsements limit provided by WIN Semiconductors Corp. to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.

2. The guarantees and endorsements limit provided by WIN Semiconductors Corp. and its subsidiaries to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant. The individual guarantee amount should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.

3. Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd., Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd., Jiangsu Win Yield Agriculture Development Co., Ltd., Jiangsu Win Shine Agriculture Development Co., Ltd., Jiangsu Win Shine Agriculture Development Co., Ltd., Jiangsu Win Sotuce Agriculture Development Co., Ltd., Jiangsu Win Sotuce Agriculture Development Co., Ltd., Jiangsu Win Sotuce Science S

Note 4: Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.'s operating procedures of guarantee and endorsement were as follows:

1. The individual guarantee amount should not exceed 30% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.

2. The guarantees and endorsements limit provided by Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd. to other parties should not exceed 50% of its equity based on the most recent audited or reviewed financial statement by a certified accountant.

Note 5: The aforementioned amount was translated at the exchange rate on the balance sheet date from USD to NTD and RMB to USD for NTD 28.63 and USD 0.1574, respectively.

Note 6: Fill in "Y" for those cases of provision of endorsements/ guarantees by listed parent company to subsidiary, provision by subsidiary to listed parent company, and provision to the party in mainland China.

59

Schedule C Securities held as of March 31, 2022 (excluding investment in subsidiaries, associates and joint ventures):

						(In thousands of	of New Taiwar	1 Dollars)
	Category and	Relationship		Shares/ Units	Ending	balance		
Name of holder	name of security	with the company	Account title		Carrying value	Percentage of ownership (%)	Fair value	Remark
The Company	Lin BioScience, Inc./Stock	None	Current financial assets at fair value through profit or loss	55	14,197	0.08	14,197	
WIN Venture Capital Corp.	Capital Money Market Fund	//	"	915	14,913	-	14,913	
WIN Chance Investment Corp.	Capital Money Market Fund	//	11	332	5,406	-	5,406	
WIN Earn Investment Corp.	Capital Money Market Fund	//	11	1,352	22,041	-	22,041	
1					56,557		56,557	
The Company	MagiCapital Fund II L.P.	//	Non-current financial assets at fair value through profit or loss	-	463,245	5.81	463,245	
"	CDIB Capital Growth Partners L.P.	//	11	-	179,314	3.30	179,314	
"	CDIB Capital Healthcare Ventures II L.P.	//	11	-	25,151	1.61	25,151	
"	Fuh Hwa Oriental Fund	//	11	15,000	24,600	-	24,600	
"	Fuh Hwa Smart Energy Fund	//	"	12,000	81,312	-	81,312	
//	LeaSun Winion L.P.	//	"	-	28,200	12.47	28,200	
//	NFC Fund II L.P.	//	"	-	306,496	32.88	306,496	
//	Foryou Venture Capital L.P.	//	"	-	30,840	5.77	30,840	
//	Renaissance Capital Limited Partnership	//	"	-	100,000	12.82	100,000	
//	Lian Ding Capital Investments Limited Partnership	//	"	-	222,000	10.23	222,000	
"	NFC Fund III, L.P.	//	"	-	81,568	19.90	81,568	
Win Semiconductors Cayman Islands Co., Ltd.	Vanchip (Tianjin) Technology Co., Ltd./Stock	Client	"	1,800	398,433	0.50	398,433	
					1,941,159		1,941,159	
The Company	Sino-American Silicon Products Inc./Stock	None	Non-current financial assets at fair value through other comprehensive income	529	93,633	0.09	93,633	
"	Inventec Solar Energy Corporation/Stock	//	"	34,000	-	10.51	-	(Note 1)
"	CDIB Capital Creative Industries Limited/Stock	//	"	3,000	20,400	3.33	20,400	
//	MagiCap Venture Capital Co., Ltd./Preferred Stock A	"	"	634	61,299	18.28	61,299	
//	New Future Capital Co., Ltd./Stock	"	"	10,000	97,700	15.87	97,700	
"	Grand Fortune Venture Corp./Stock	"	"	4,000	62,240	6.87	62,240	
"	NFC I Renewable Power Co., Ltd./Stock	"	"	16,200	159,408	15.00	159,408	
"	Gogolook Co., Ltd./Stock	"	"	2,013	133,559	11.83	133,559	
Win Semiconductors Cayman Islands Co., Ltd.	Broadcom Ltd./Stock	Client	//	75	1,352,080	0.02	1,352,080	
"	Anokiwave Inc./Series B Preferred Stock	"	"	1,264	75,928	7.93	75,928	
WIN Venture Capital Corp.	MOAI Green Power Corporation/Stock	None	"	90	-	0.28	-	
"	Merit Biotech INC./Stock	"	"	1,320	-	2.93	-	(Note 2)
"	Winresp INC./Stock	"	"	2,740	40,857	14.14	40,857	
					2,097,104		2,097,104	

Note 1: The Board of Directors of Inventec Solar Energy Corporation had declared to bankruptcy the company in December 2021. As of March 31, 2022, the company was still within the period of liquidation. Note 2: The Board of Directors of Merit Biotech INC. had resolved to dissolve and liquidate the company in 2017. As of March 31, 2022, the company was still within the period of liquidation.

Schedule D Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the Company's paid in capital:

												(III thousands of	New Talwa	II Donais)	
	Category and		Name of	Relationship	Begir	ning	Purc	hases			Sales		Ending		
Name of Company	name of security	Account name		with the Company	Shares (in thousands)	Amount	Shares (in thousands)	Amount	Shares (in thousands)	Price	Cost	Gain (loss) on disposal	Shares (in thousands)	Amount	
Chainwin Biotech and Agrotech	Jiangsu Chainwin Kang Yuan	Investments accounted for using equity method	-	subsidiary	-	3,167,667	-	560,600	-	-	-	-		2,832,850	
(Cayman Islands) Co., Ltd.	Agricultural Development Co., Ltd.													(Note 1)	
"	Jiangsu Win Yield Agriculture	"	-	"	-	1,932,345	-	361,790	-	-	-	-		2,374,200	
	Development Co., Ltd.													(Note 1)	

Note 1: The amount of ending balance was calculated using the equity method. The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

Schedule E Information on acquisition of real estate with purchase amount exceeding the lower of NT\$300 million or 20% of the Company's paid in capital:

											(ln	thousands c	of Dollars)
								e counter-party se the previous					1
Name of	Name of Property	Transaction Date	Transaction	Status of payment	Counter-party	Relationship with the	discio	Relationship	s transfer into	mation	References for	Purpose of	Others
Company	Name of Property	Halisaction Date	amount	Status of payment	Counter-party	Company	Owner	with the	Date of transfer	Amount	determining price	acquisition	Oulers
								Company	transier				
The Company	Factory buildings	2021/4/6~2021/5/25		As of March 31, 2022, the price paid	Chung-Lin General	-	N/A	N/A	N/A	N/A	Price negotiation	Operating	None
				\$454,395 thousand.	Contractors, Ltd.							purpose	i i
"	Factory buildings	2021/10/15		As of March 31, 2022, the price paid	Chung-Lin General	-	N/A	N/A	N/A	N/A	Price negotiation	Operating	None
				\$697,430 thousand.	Contractors, Ltd.							purpose	1
Jiangsu Chainwin Kang Yuan Agricultural Developm	ent Co., Ltd. Factory buildings	2018/10/25		As of March 31, 2022, the price paid	Jiangsu Nantong Sanjian	-	N/A	N/A	N/A	N/A		Operating	None
			(1000,575)	\$593,246 thousand (RMB 131,646 thousand).	Construction Group Co., Ltd.						1 0	purpose	i i
"	Factory buildings	2020/12/23	, . <i>.</i> ,	As of March 31, 2022, the price paid	Jiangsu Huaitian Construction	-	N/A	N/A	N/A	N/A	Price comparison and	Operating	None
			(RMB 555,700)	\$1,259,818 thousand (RMB 279,564 thousand).	Ltd.						price negotiation	purpose	i i
Jiangsu Chainwin Agriculture and Animal Technolog	y Co., Ltd. Factory buildings	2018/11/20		As of March 31, 2022, the price paid	Jiangsu Nantong Sanjian	-	N/A	N/A	N/A	N/A	Price comparison and	Operating	None
			(RMB 173,365)	\$742,183 thousand (RMB 164,697 thousand).	Construction Group Co., Ltd.						price negotiation	purpose	i i
Jiangsu Win Yield Agriculture Development Co., Ltd	. Factory buildings	2020/1/10	1,482,045	As of March 31, 2022, the price paid	Jiangsu Nantong Sanjian	-	N/A	N/A	N/A	N/A	Price comparison and	Operating	None
			(RMB 342,511)	\$1,473,580 thousand (RMB 327,000 thousand).	Construction Group Co., Ltd.						price negotiation	purpose	1
п	Factory buildings	2020/12/8		As of March 31, 2022, the price paid	Jiangsu Huaitian Construction	-	N/A	N/A	N/A	N/A	Price comparison and	Operating	None
			(RMB 268,600)	\$1,089,020 thousand (RMB 241,663 thousand).	Ltd.						price negotiation	purpose	1
"	Factory buildings	2021/2/8		As of March 31, 2022, the price paid	Jiangsu Huaitian Construction	-	N/A	N/A	N/A	N/A	Price comparison and	Operating	None
			(RMB 125,000)	\$506,966 thousand (RMB 112,500 thousand).	Ltd.						price negotiation	purpose	1
"	Factory buildings	2021/5/12~2021/8/25		As of March 31, 2022, the price paid	Jiangsu Huaitian Construction	-	N/A	N/A	N/A	N/A	Price comparison and	Operating	None
			(RMB 170,600)	\$681,475 thousand (RMB 151,225 thousand).	Ltd.						price negotiation	purpose	1
													1
													·

(In thousands of New Taiwan Dollars)

(In thousands of Dollars)

Schedule F Information regarding receivables from related-parties exceeding the lower of NT\$100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

							(,
Name of Company	Name of Counter-party	Relationship	Ending	Turnover		Overdue	Amounts received	Allowances
Name of Company	Name of Counter-party	Relationship	balance	rate	Amount	Action taken	in subsequent period	for bad debts
Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	Affiliate	114,730	(Note 1)	-	-	-	(Note 2)
Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	Affiliate	169,382	(Note 1)	-	-	156,518	(Note 2)

Note 1: The ending balance was other receivables, which was not applicable for the calculation of turnover rate.

Note 2: The amount of the transaction had been offset in the consolidated financial statements.

Schedule G Business relationships and significant inter company transactions:

Number			Nature of	Intercompany transactions							
(Note 1)	Name of Company	Name of Counter-party	relationship (Note 2)	Account name	Amount (Note 3)	Trading terms	Percentage of the consolidated net revenue or total assets				
1	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	3	Other receivables due from related parties	114,730	no difference with non-related parties	0.15%				
2	Jiangsu Win Yield Agriculture Development Co., Ltd.	Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd.	3	Other payables due to related parties	114,730	no difference with non-related parties	0.15%				
3	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	Jiangsu Win Yield Agriculture Development Co., Ltd.	3	Other receivables due from related parties	169,382	no difference with non-related parties	0.23%				
2	Jiangsu Win Yield Agriculture Development Co., Ltd.	Jiangsu Chainwin Kang Yuan Agricultural Development Co., Ltd.	3	Other payables due to related parties	169,382	no difference with non-related parties	0.23%				

Note 1: Company numbering as follows:

Parent company -0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary-1

Subsidiary to parent company-2

Subsidiary to subsidiary-3

Note 3: The amount of the transaction had been offset in the consolidated financial statements...

(In thousands of New Taiwan Dollars)

Schedule H Information on investments:

The following is the information on investees as of March 31, 2022 (excluding information on investees in mainland China):

									(In thousand	s of New Taiw	van Dollars)
			Main	Original inves	stment amount	The en	ding balance at this pe	eriod	Net income	Investment	
Name of investor	Name of investee	Location	businesses and	The ending balance	The ending balance	Shares	Percentage of	Carrying	(losses)	income (losses)	Remark
			products	at this year	at the beginning	(in thousands)	ownership	value	of investee	income (iosses)	
The Company	WIN SEMI. USA, INC.	California USA	Marketing	8,203	8,203	1,000	100.00%	(15,044)	(4,323)	(4,323)	(Note 1)
//	Win Semiconductors Cayman	Cayman Islands	Investment activities	11,127,774	11,127,774	376,600	100.00%	10,658,061	(371,632)	(371,632)	(Note 1)
	Islands Co., Ltd.										
"	WIN Venture Capital Corp.	Taiwan	Investment activities	790,000	790,000	79,000	100.00%	828,432	6,193	6,193	(Note 1)
"	Phalanx Biotech Group, Inc.	Taiwan	Researching, manufacturing and selling of high-density	1,079,169	1,079,169	53,427	73.67%	612,817	(36,880)	(27,168)	(Note 1)
			gene chips and testing service								
"	WIN Chance Investment Corp.	Taiwan	Investment activities	580,000	580,000	58,000	100.00%	682,290	6,788	6,788	(Note 1)
"	WIN Earn Investment Corp.	Taiwan	Investment activities	580,000	580,000	58,000	100.00%	459,660	6,112	6,112	(Note 1)
"	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	6,120,993	6,120,993	65,409	17.08%	8,006,862	809,113	95,148	
			copper-clad laminates, prepreg, and electronic components.								
WIN Venture Capital Corp.	Phalanx Biotech Group, Inc.	Taiwan	Researching, manufacturing and selling of high-density	39,600	39,600	1,116	1.54%	30,206	(36,880)	(Note 2)	(Note 1)
			gene chips and testing service								
//	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	713,036	713,036	5,301	1.39%	742,147	809,113	(Note 2)	
			copper-clad laminates, prepreg, and electronic components.								
Win Semiconductors Cayman	Rainbow Star Group Limited	British Virgin	Investment activities	62,920	62,920	38	49.30%	54,698	(572)	(Note 2)	
Islands Co., Ltd.	<u>^</u>	Islands									
//	Chainwin Biotech and Agrotech	Cayman Islands	Investment activities	10,905,959	10,905,959	185,054	81.23%	8,762,515	(463,512)	(Note 2)	(Note 1)
	(Cayman Islands) Co., Ltd.										
Chainwin Biotech and Agrotech	i-Chainwin Technology (Cayman	"	Investment activities	194,670	194,670	6,500	100.00%	151,858	(23)	(Note 2)	(Note 1)
(Cayman Islands) Co., Ltd.	Islands) Co., Ltd.										
//	Win Lux Biotech (Cayman Islands)	"	Investment activities	15,010	15,010	500	100.00%	12,021	(23)	(Note 2)	(Note 1)
	Co., Ltd.										
//	i-Chainwin Technology Co., Ltd.	Taiwan	Information software services	220,000	220,000	22,000	100.00%	149,651	(3,693)	(Note 2)	(Note 1)
"	Win Lux Biotech Co., Ltd.	Taiwan	Biotechnology services and pharmaceutical testing	100,000	100,000	10,000	100.00%	72,020	(15,741)	(Note 2)	(Note 1)
Phalanx Biotech Group, Inc.	Phalanx Biotech Limited.	Hong Kong	Investment activities	12,125	12,125	-	100.00%	2,331	(1,209)	(Note 2)	(Note 1)
//	PhalanxBio, Inc.	USA	Selling of high-density gene chip and test service	208,110	208,110	2,550	100.00%	19	55	(Note 2)	(Note 1)
//	Guzip Biomarkers Corporation	Taiwan	Development and sales of test reagents for endometrial cancer	81,727	81,727	14,238	100.00%	10,766	(392)	(Note 2)	(Note 1)
WIN Chance Investment Corp.	ITEQ Corporation	Taiwan	Manufactures and sells mass lamination boards,	595,251	595,251	4,702	1.23%	676,949	809,113	(Note 2)	
	*		copper-clad laminates, prepreg, and electronic components.								
WIN Earn Investment Corp.	ITEQ Corporation	Taiwan	"	568,005	568,005	4,230	1.10%	437,689	809,113	(Note 2)	

Note 1: The amount of the transaction had been offset in the consolidated financial statements.

Note 2: The share of profit (loss) of the investee company is not reflected herein as such amount is already included in the share of profit (loss) of the investor company.

Schedule I Information on investment in mainland China:

(i) The names of investees in mainland China, the main businesses and products, and other information:

						lated outflow					lated outflow			Direct/Indirect	Inv	restment		ying value	(In thousands Accumulated	s of Dollars
Name of	Main businesses	Total am		Method of		stment from	lı	nvestment f	lows	of investment from Net income (losses)			percentage of		ne (losses)	at the end		remittance of	Remark	
investee	and products	of paid in c	capital	investment		wan at the ng of this year	-				wan as of	of the	investee	ownership by the		4)(Note 6)	of this period (Note 5)		earnings in current	
					beginnir	6	Ou	tflow	Inflow	Marc	h 31, 2022			Company	-		(1	,	period	
Jiangsu Chainwin Kang Yuan	Developing hog farming technology	· · · · ·	28,267	(Note 1)		2,748,422		560,600	-		3,309,022		(277,031)	81.23%		(277,031)		2,832,850	-	(Note 10)
Agricultural Development Co., Ltd.	and trading	·	7,767)		(USD	93,043)	(USD	20,000)		(USD	113,043)	(USD	(9,879))		(USD	(9,879))	(USD	98,947)		
Jiangsu Chainwin Agriculture and	Farm feed developing and trading	· · · · ·	69,119	(Note 1)		1,146,255		-	-		1,146,255		(15,468)	81.23%		(15,468)		1,116,816	-	(Note 10)
Animal Technology Co., Ltd.		·	8,790)		(USD	38,046)				(USD	38,046)	(USD	(547))		(USD	(547))	(USD	39,009)		
Jiangsu CM/Chainwin Agriculture	Developing hog farming technology		59,210	(Note 1)		1,122,874		-	-		1,122,874		(68,760)	39.80%		(33,693)		664,075	-	
Development Co., Ltd.	and trading	·	67,584)		(USD	36,821)				(USD	36,821)	(USD	(2,462))		(USD	(1,207))	(USD	23,195)		
Jiangsu Win Chance Agriculture	Developing hog farming technology		10,094	(Note 1)		507,992		143,150	-		651,142		(28,591)	81.23%		(28,591)		524,386	-	(Note 10)
Development Co., Ltd.	and trading	(USD 2	.0,200)		(USD	16,569)	(USD	5,000)		(USD	21,569)	(USD	(1,030))		(USD	(1,030))	(USD	18,316)		
Jiangsu Merit/Cofcojoycome	Developing hog farming technology		-	(Note 1)		149,664		-	-		149,664		-	-		-		-	-	(Note 8)
Agriculture Development Co., Ltd.	and trading				(USD	4,872)				(USD	4,872)									
Jiangsu Merit Runfu Agriculture	Developing hog farming technology		72,313	(Note 1)		41,009		-	-		41,009		-	81.23%		-		8,533	-	(Note 10)
Development Co., Ltd.	and trading	(RMB 1	6,177)		(USD	1,335)				(USD	1,335)						(USD	298)		
Jiangsu Win Yield Agriculture	Developing hog farming technology	2,2	94,135	(Note 1)		1,737,325		361,790	-		2,099,115		(29,644)	81.23%		(29,644)		2,374,200	-	(Note 10)
Development Co., Ltd.	and trading	(USD 7	9,500)		(USD	59,500)	(USD	13,000)		(USD	72,500)	(USD	(1,050))		(USD	(1,050))	(USD	82,927)		
Jiangsu Win Shine Agriculture	Logistics management service	34	45,130	(Note 1)		85,170		-	-		85,170		(4,557)	81.23%		(4,557)		337,656	-	(Note 10)
Development Co., Ltd.		(USD 1	2,000)		(USD	3,000)				(USD	3,000)	(USD	(163))		(USD	(163))	(USD	11,794)		
Jiangsu Win Boutique Agriculture	Developing hog farming technology	2	88,100	(Note 1)		-		-	-		-		(1,999)	81.23%		(1,999)		250,890	-	(Note 10)
Development Co., Ltd.	and trading	(USD 1	0,000)									(USD	(73))		(USD	(73))	(USD	8,763)		
Jiangsu Win Sunlight Agriculture	Developing hog farming technology	2	88,100	(Note 1)		86,430		-	-		86,430	·	(2,567)	81.23%	-	(2,567)	-	245,459	-	(Note 10)
Development Co., Ltd.	and trading	(USD 1	0,000)		(USD	3,000)				(USD	3,000)	(USD	(93))		(USD	(93))	(USD	8,574)		
Jiangsu Win Honor Management	Logistics management service	2	88,100	(Note 1)		-		-	-	`	-		(811)	81.23%	`	(811)	`	279,692	-	(Note 10)
Technology Co., Ltd.	0 0	(USD 1	0,000)									(USD	(30)		(USD	(30))	(USD	9,769)		
Jiangsu Win Wonder Agriculture	Developing farming technology		88,173	(Note 3)		-		-	-		-	`	(4,057)	81.23%		(4,057)	`	83,706	-	(Note 10)
Development Co., Ltd.	and trading		0,000)	(-)								(RMB	(912))		(RMB		(RMB	18,575)		
Jiangsu Win Fortune Agriculture	Developing hog farming technology	·	76,400	(Note 1)		221,120		-	-		221,120		(1,693)	81.23%		(1,693)	`	270,170	-	(Note 10)
Development Co., Ltd.	and trading		0,000)	· · ·	(USD	8,000)				(USD	8,000)	(USD	(62))		(USD	(62))	(USD	9,437)		
Chainwin (Huaian) AloT Co., Ltd.	Information software services		27,860	(Note 1)	(27,860		-	-	(27.860	((267)	81.23%	((267)	(25,049	-	(Note 10)
			1.000)	((USD	1,000)				(USD	1.000)	(USD	(10))		(USD	(10))	(USD	875)		(
Jiangsu Win Advance Bio-Assay Co., Ltd.	Biotechnology testing service	·	11,560	(Note 1)	(000	-			-	(000	-	(000	(364)	81.23%	(000	(364)	·	113,422	-	(Note 10)
nangsa (fini farance Bio fissa) con, Eta.	Disteriniology testing set fier		4,000)	(11010-1)								(USD	(13))	0112570	(USD	(13))		3,962)		(11010-110)
Jiangsu Win Lux Biotech Co., Ltd.	Biotech research and development and		27,680	(Note 1)		27,680		-	-		27,680	(000	(365)	81.23%	(555	(365)	·	27,945	-	(Note 10)
siangsu win Eux Bioteen Co., Etd.	bioassay		1,000)	(1000 1)	(USD	1,000)		-	-	(USD	1,000)	(USD	(13))	01.2370	(USD	(13))	(USD	976)	-	(11010-10)
Onearray Biotech (Kunshan) Co., Ltd.	Selling of high density gene chip		12,125	(Note 2)	(030	1,000)		-	_	(030	1,000)	(000	(1,209)	75.21%	(000	(1,209)	(030	2,352		(Note 10)
Oncarray Bioteen (Kufishafi) Co., Ltd.			· ·	(11010 2)	(USD	420)		-	-	(USD	420)	(RMB	(1,209)	/ 3.2170	(RMB	,	(RMB	522)	-	(10010-10)
	and test service	(KMB	2,663)		USD	420)				USD	420)	(KIMB	(274))		(KIVIB	(274))	CKMB	322)		

(ii) Limitation on investment in mainland China:

			(In thousands of Dollars)
Investor Company Name	Accumulated Investment in mainland China at the end (Note 7)(Note 8)	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment (Note 9)
The Company and subsidiaries	9,240,886 (USD 313,989)		20,937,555

Note 1: The Group invested in mainland China companies through Chainwin Biotech and Agrotech (Cayman Islands) Co., Ltd , which is established in a third region.

Note 2: The Group invested in mainland China companies through Phalanx Biotech Limited, which is established in a third region.

Note 3: The Company invested in mainland China companies through Jiansu Win Chance Agriculture Development Co., Ltd.

Note 4: The amount of net income (losses) was recognized based on the reviewed financial statements of the investee companies.

Note 5: Carrying value as of March 31, 2022 was with reference to the amount recognized by the investment through subsidiaries to subsidiaries established in a third region.

Note 6: Investment income (loss) recognized was translated into New Taiwan Dollars at the average exchange rate for the each month from January 1 to March 31, 2022.

Note 7: The Group acquired Vanchip (Tianjin) Technology Co., Ltd. through a third region, wherein the outflow of investment from Taiwan amounted US\$9,383 thousand (NT\$261,420 thousand).

Note 8: Jiansu Merit/Cofcojoycome Agriculture Development Co., Ltd. had been liquidated on January 25, 2019. However, according to the regulation of Investment Commission the remittance to mainland China amounting to US\$4,872 thousand (NT\$149,664 thousand) was included in the accumulated investment account.

Note 9: Amount of upper limit on investment was the higher between sixty percentage of total equity or total consolidated equity.

Note10: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

(iii) Significant transactions: Please refer Schedule A, Schedule B, Schedule D, Schedule F and Schedule G.

Schedule J Information on major shareholders:

		(In shares)
Shareholding Shareholder's Name	Shares	Percentage
Cathay Life Insurance Co.,Ltd.	21,787,000	5.13%